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ABSTRACT 
Sarah Elizabeth Wetzel-Strong: Effect of adrenomedullin over-expression in the cardiovascular 
system during development and disease 
(Under the direction of Kathleen Caron)
 
 Since the discovery of adrenomedullin (Adm – gene; AM – protein) in 1993, many roles 
for this widely expressed peptide have been described in the cardiovascular system. Numerous 
studies have determined that circulating levels of AM in human blood are elevated during many 
disease conditions, leading to questions about the feasibility of using this peptide as a 
biomarker of disease severity, as well as inquiries into the function of elevated AM in these 
contexts. In order to evaluate the effect of elevated AM during disease, gene-targeting 
techniques were used to generate mice that constitutively over-express Adm, abbreviated as 
Admhi/hi. The initial phenotypical analysis of this line revealed that Admhi/hi mice have enlarged 
hearts due to hyperplasia during development. Through genetic approaches, we determined 
that Adm over-expression primarily in the epicardium promotes this cardiac hyperplasia.  
 Analysis of Adm expression levels between male and female Admhi/hi animals led to the 
unexpected finding that female Admhi/hi mice express Adm at levels 60-times greater than 
wildtype controls in the heart; whereas Admhi/hi males over-express Adm by 3-fold in the heart. 
Previous studies have demonstrated that Adm expression can be induced by estrogen; 
however, the potential for estrogen-induced negative regulation of Adm had not been explored. 
We found that many estrogen-induced microRNAs target the 3"UTR of Adm, including the novel 
microRNA, miR-879, to balance Adm expression in the female heart.  
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 Finally, many groups have demonstrated that AM provides protection to the heart during 
cardiovascular disease. Nonetheless, whether the physiological elevation of AM during human 
disease affects disease progression remains unknown. We asked whether constitutive over-
expression of AM in the context of chronic hypertension provided any benefit by crossing the 
renin transgenic mouse model of hypertension to the Admhi/hi line. From this study, we found that 
Adm over-expression did not alter the degree of hypertrophy or fibrosis in the heart. However, 
the results from this study are inconclusive, as the renin transgenic mice with wildtype levels of 
Adm did not exhibit the cardiac fibrosis previously reported, indicating that the mixed genetic 
background of our experimental animals alters cardiovascular pathology independent of Adm 
status.
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CHAPTER I: ROLE OF ADRENOMEDULLIN IN THE CARDIOVASCULAR SYSTEM 
Overview of adrenomedullin
 Adrenomedullin (Adm = gene; AM = protein) is a highly conserved, 52-amino acid 
peptide originally isolated from pheochromocytoma, a tumor derived from the medulla cells of 
the adrenal gland, in 1993 (108). Additional studies have revealed that AM is ubiquitously 
expressed in normal tissues beginning during embryonic development and continuing into the 
adult. In mice, expression of Adm within embryonic tissues begins at e8.0 in the heart (152, 
153). By e10, expression of Adm has increased in the heart and other tissues within the embryo 
have begun to express Adm (152, 153). The early and widespread expression of AM during 
development indicates an important role for this peptide during embryonic development. This 
assertion is supported by the fact that several groups have demonstrated an essential role for 
AM in proper embryonic development and shown that AM is absolutely critical for survival (24, 
59, 203, 204). These studies have revealed that the ablation of AM in mice results in 
cardiovascular abnormalities (24, 204), in addition to abnormalities in the development of the 
lymphatic system (24, 59), ultimately leading to embryo demise between e13.5 and e14.5. 
Specifically, the hearts of Adm-/- embryos are smaller compared to wildtype littermates, 
characterized by a thin compact zone and enhanced trabeculation (24). Furthermore, studies by 
Fritz-Six et al determined that the loss of other AM signaling system components results in a 
reduction of jugular lymph sac size due to decreased lymphatic proliferation (59). Together, 
these findings indicate that AM signaling is required for modulating proliferation in subsets of 
cells, which is further supported by recent work published by Wetzel-Strong et al demonstrating 
that over-expression of Adm promotes cardiac hyperplasia (245). 
 2 
 Several approaches have been utilized to elucidate the function of AM, including the 
infusion of AM peptide into animal models and human patients (77, 78, 98, 107, 157-159, 165, 
166, 170, 173, 223, 228), the study of Adm heterozygous (Adm+/-) animals during disease (20, 
171, 203), and most recently, the study of Adm over-expressing mice (245). These studies have 
revealed that AM has a multitude of functions depending on the scenario, including, but not 
limited to: antioxidant (19), anti-inflammatory (37), anti-microbial (4), vasodilatory (108, 132), 
anti-fibrotic (168), anti-hypertrophic (140, 231), inotroptic (87), and angiogenic (60, 106) 
properties. Given the many diverse functions of AM, it is not surprising that several factors, 
including estrogen (240), angiotensin II (AngII) (175, 215), glucocorticoids (80), cytokines (215), 
and hypoxia inducible factor-1α (HIF-1α) (39), can induce Adm expression via association with 
upstream response elements. The control of Adm expression by many different factors 
facilitates fine-tuned control of Adm in specific cell populations, and thus permits localized action 
of AM in response to specific stimuli. Finally, as expected, the diverse functions of Adm can 
have broad implications during human disease. Depending on the disease condition, these 
effects may be beneficial or detrimental to an individuals overall health, as discussed in greater 
detail in later sections.  
 
Adrenomedullin structure and signaling 
The gene encoding adrenomedullin, located on chromosome 11 in humans and 
chromosome 7 in mice, produces a 185-amino acid precursor peptide, referred to as 
preproadrenomedullin (53). Post-translational processing of preproadrenomedullin results in the 
production of proadrenomedullin N-terminal 20 peptide (PAMP) in addition to the immature 
glycine-extended AM (109). Biological activity of AM is dependent on the presence of several 
key features, including amidation of the C-terminus (109), which is catalyzed by peptidylglycine 
alpha-amidating monooxygenase (PAM) and a disulfide bridge between cysteine residues 
located at positions 16 and 21 (108). These key features are conserved between several 
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members of the calcitonin peptide superfamily, including calcitonin gene-related peptide 
(CGRP), amylin (108), and AM, indicating the relationship between these peptides (Figure 1). 
Although several features critical to the activity of AM have been characterized, to date, 
a limited amount of information is available regarding the three-dimensional structure of AM. 
Recently, Pérez-Castells et al have reported the structure of AM when associated with SDS-
micelles (181). In this situation, AM comprises an α-helix spanning amino acids 22 to 34, while 
the flanking regions remain disorganized. The authors note that AM did not organize in the 
presence of cholesterol or ergosterol, indicating that the α-helix of AM may allow for the 
preferential association with cell membranes of bacteria, to ultimately promote the destruction of 
the bacterial cell, while leaving the host cells unaffected (181). This finding is interesting since it 
suggests a function of AM independent of receptor binding. However, since binding of AM to its 
receptor is believed to account for the majority of the actions of AM, it remains to be determined 
whether the structure of AM bound to the receptor complex differs drastically from the micelle-
bound structure.    
After the discovery of AM, many groups sought to identify the receptor through which AM 
mediated its effects. Initially, several receptors, including the G-protein coupled receptor 
(GPCR) AM-R (95), now known as GPR182, as well as the GPCR RDC-1 (96), now identified 
as ACKR3 were identified as AM receptors. Although these initial studies showed an increase in 
cAMP when COS-7 cells were transfected with either putative receptor and treated with AM, 
these results could not be repeated by other groups for the AM-R (99), leading to its re-
orphanization. The discovery of receptor activity-modifying proteins, abbreviated as RAMPs, in 
1998 (145) brought about significant changes in the understanding of GPCR signaling. Studies 
of the RAMPs have revealed that these single-pass transmembrane proteins serve a number of 
functions in the cell (16, 145). The initial characterization of the RAMPs by McLatchie and 
colleagues showed that association of RAMPs with the GPCR calcitonin receptor-like receptor 
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(Calcrl = gene, CLR = protein) increased trafficking of CLR to the cellular membrane (145). This 
study also revealed that RAMPs can modulate GPCR ligand affinity (145). In this particular 
case, McLatchie et al found that the association of CLR with RAMP1 produced a receptor that 
favored calcitonin gene-related peptide (CGRP), while the association of RAMP2 or RAMP3 
with CLR resulted in a receptor favoring AM (145). Finally, Bomberger et al demonstrated that 
RAMP3 is capable of recycling CLR to the plasma membrane after endocytosis (16), indicating 
that the RAMP associated with a receptor can modulate the length of time a cell will respond to 
a particular ligand (Figure 2). 
 The identification of the RAMPs was paradigm-shifting for the field of GPCR biology and 
prompted a series of investigations into the role RAMPs play in vivo. Thus, several groups 
proceeded to generate knockout animals for each of the RAMPs (41, 230). Tsujikawa et al (230) 
found that the complete loss of RAMP1, achieved by gene-targeted deletion of exon 2 of the 
mouse RAMP1 gene, produced viable mice with an overtly normal phenotype; although the 
adult Ramp1-/- animals were hypertensive compared to control animals. These findings reflect 
the results of earlier studies utilizing α-CGRP knockout mice (63, 137), indicating that CGRP 
signaling, primarily via the CLR/RAMP1 interface, while not required for proper embryonic 
development, may play an important role in blood pressure regulation. However, in contrast to 
these findings, an independent mouse model of Ramp1 loss published recently by Li et al (127) 
found that although the loss of RAMP1 is compatible with life, changes in blood pressure were 
not observed. This difference could perhaps be attributed to differences in the genetic 
background of the Ramp1 knockout mice. Studies of RAMP2 knockout mice revealed that this 
RAMP is essential for survival (41, 59). These studies revealed that Ramp2-/- embryos have 
small lymphatic vessels due to decreased proliferation, ultimately contributing to severe hydrops 
fetalis and fetal demise around e14.5 (59). In addition to severe defects in lymphatic 
development, Ramp2-/- mice have abnormal hearts characterized by an overall small size and 
thin compact zone compared to wildtype controls (59). The phenotype observed in the Ramp2-/- 
 5 
mice closely mirrors the phenotype observed not only in the Adm-/- animals (24), but also in 
Calcrl-/- mice (42), indicating that CLR/RAMP2 is the primary receptor for mediating the effects 
of AM during embryonic development. Finally, the loss of RAMP3 in mice does not disrupt 
embryonic development (41), further supporting the conclusion that the effects of AM during 
development are mediated primarily via the CLR/RAMP2 complex. Interestingly, the loss of 
RAMP3 does inhibit weight gain in aged mice (41), and exacerbates cardiovascular disease in 
the context of chronic hypertension (8), indicating a role for RAMP3 in modulating AM signaling 
in normal physiology and pathological conditions in adult animals. Together, the published 
studies examining the roles of RAMPs in vivo have demonstrated the differential role for each 
RAMP during embryonic and adult stages. However, additional studies are needed to determine 
what GPCRs are associating with the RAMPs to elicit the observed effects and to determine the 
role of each RAMP during disease. 
 
Roles of adrenomedullin in cardiovascular disease 
Hypertension is a disease in which the blood pressure is chronically elevated. This 
persistent elevation in blood pressure promotes several pathological changes, including 
cardiomyocyte hypertrophy, damage to the vasculature, and renal damage. Several studies 
have indicated that AM is a powerful vasodilator (108, 132), and therefore, may mitigate 
cardiovascular and renal damage in the context of hypertension by working to lower blood 
pressure. To determine if AM is protective in hypertension, numerous groups have used animal 
models to address the role of AM during hypertensive cardiovascular disease. Overall, these 
studies have demonstrated a protective role for AM; however, the direct effects of AM are varied 
depending on the study design.  
One approach that has been taken to study the role of AM in the context of hypertension 
is the utilization of Adm+/- mice (20, 171, 203). In one such study, Shimosawa and colleagues 
induced hypertension by infusion of AngII combined with salt-loading in Adm+/- mice (203). With 
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this model, a 50% reduction of AM resulted in exacerbated perivascular fibrosis in the heart, 
however blood pressure was unaffected (203), indicating that AM exerts protective effects 
independent of its vasodilatory effects. Niu et al assessed the effect of decreased AM on 
cardiovascular health by challenging Adm+/- mice with either AngII infusions or transverse aortic 
constriction (171). The reduction of AM in both of these models promoted an exacerbation of 
cardiovascular disease pathology, characterized by increased cardiomyocyte hypertrophy and 
increased interstitial fibrosis in the heart (171). Additionally, Niu et al found that renal damage 
was augmented in Adm+/- mice following AngII infusion (171). Finally, Caron et al utilized the 
renin transgene (RenTgMK) mouse model of chronic hypertension to assess the impact of 
reduced AM in both male and female mice (20). Similar to observations made by Shimosawa et 
al (203), Caron et al found that a 50% reduction in AM failed to alter blood pressure (20). 
Interestingly, Caron et al found that males were more adversely affected by a reduction in AM, 
while females were largely unaffected (20). In particular, Caron et al found that cardiomyocyte 
hypertrophy and renal damage were enhanced in RenTgMK+:Adm+/- males compared to 
RenTgMK+:Adm+/+ males (20), reflecting some of the findings by Niu et al (171). Overall, these 
studies utilizing Adm heterozygous mice have revealed that AM has protective properties in the 
heart and kidneys independent of alterations to blood pressure in the context of hypertension. 
Since the studies described above revealed a worsening of cardiovascular outcome with 
a 50% reduction of AM, researchers were then interested in determining whether over-
expression of AM in the context of hypertension afforded additional protection to, thereby, 
further solidify the function of AM as a cardioprotective peptide (170, 237, 243). Using Dahl salt-
sensitive rats, Nishikimi et al demonstrated that infusion of human AM resulted in a small 
decrease in blood pressure after induction of hypertension through a high salt diet compared to 
vehicle-treated rats (170). This study also revealed that AM infusion improved cardiac output 
and reduced systemic vascular resistance, which presumably contributes to the improved 
survival of rats that received AM (170). Wei et al used adeno-associated virus (AAV) to deliver 
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either the gene for GFP or human AM to spontaneously hypertensive rats (243). Compared to 
animals receiving the AAV expressing GFP, animals that received the AAV expressing AM had 
a significant reduction of blood pressure, decreased cardiomyocyte hypertrophy, reduced 
interstitial fibrosis in the heart, and diminished renal damage (243), further supporting the broad 
protective properties of AM in the cardiovascular and renal systems. Finally, Wang et al also 
used AAV to over-express human AM in rats (237). In contrast to the study performed by Wei et 
al (243), this study used the Goldblatt model of hypertension (70), in which a clip is placed on 
one of the renal arteries, ultimately leading to an increase in renin secretion by the clipped 
kidney and hypertension resulting from over-activation of the renin-angiotensin aldosterone 
system (RAAS) (160). Although the model of hypertension in this study differed from the model 
employed by Wei et al, the effects of AM over-expression by AAV on cardiovascular and renal 
pathology were comparable between the two studies (237). Together, these studies indicate 
that over-expression of AM is beneficial in the context of hypertension, potentially due in part to 
blood pressure reductions.  
Ischemia-reperfusion injury, commonly referred to as a heart attack in human patients, 
occurs when one of the coronary arteries, which supply blood to the ventricular tissue, becomes 
occluded due to plaque formation (247). This occlusion of the vessel deprives the underlying 
cardiac muscle of important nutrients and oxygen, ultimately resulting in death of the underlying 
cardiomyocytes (247). In order to maintain structural integrity of the heart, the infarcted, area of 
the heart is initially replenished by myofibroblasts (232). These fibroblasts deposit extracellular 
matrix, including collagen, which drastically reduces the compliance of the ventricular wall, 
leading to impaired cardiac function. Although some lower-order vertebrates, including 
zebrafish, have the capability to regenerate cardiac muscle (238, 251), higher-level vertebrates, 
including rodents and humans, have limited cardiac regenerative abilities. As a result of low 
cardiac regeneration, the fibrotic scar formed during the initial stages of wound healing persists 
for the life of the animal, resulting in reduced cardiac output and increased risk for adverse 
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cardiac events in the future. Although we currently do not have the knowledge to promote the 
replacement of scar tissue with functional cardiomyocytes in mammals, there is great interest in 
identifying molecules that can reduce the size of the infarct, which in turn, reduces the degree of 
scar tissue deposition and preserves a greater amount of cardiac function. Due to the protective 
role of AM in the context of hypertension, researchers were interested in determining if and how 
AM may be protective in the context of ischemia-reperfusion. 
In animal models, researchers mimic a heart attack by ligating the left anterior 
descending (LAD) coronary artery to promote ischemic injury to the tissue fed by the ligated 
vessel. The suture is then released, usually 30 minutes after initiation of ischemia, to reperfuse 
the tissue with blood and oxygen, thereby simulating the re-opening of a vessel after dissolving 
a clot. Using this approach, several groups have assessed the effect of AM status on injury after 
ischemia-reperfusion (77, 78, 165, 173, 223). Overall, these studies have revealed a protective 
effect of AM in this model of cardiac injury. Of the studies that assessed the impact of AM on 
infarct size, it was unanimously found that either infusion of AM or over-expression of AM by 
AAV significantly reduced infarct size (77, 78, 165, 173). Accompanying this reduction in infarct 
area, these studies also found a reduction in cardiomyocyte apoptosis (173) and improved 
recovery of left ventricular function (165). Although Torigoe et al did not assess the effect of AM 
administration on infarct size, they did report improved recovery of left ventricular function (223), 
indicating that infarct size in this model is likely reduced. Together, these studies indicate one 
way in which elevated levels of AM following myocardial infarction serve to mitigate injury is 
through a reduction in the area of tissue injured, thus leading to better prognosis. 
In addition to identifying the effect of AM on cardiac pathology after ischemia-
reperfusion, several groups sought to identify the signaling pathways by which AM mediates its 
protective effects. Several of these studies identified the PI3K/Akt pathway as an important 
mediator of the protective effects of AM (77, 173, 223). Moreover, two of these studies identified 
downstream targets of Akt signaling that may be responsible for mediating the protective effects 
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of AM, including endothelial nitric oxide synthase (eNOS) (77) and heat shock protein-72 
(HSP72). Interestingly, Nishida et al found that administration of AM immediately after ischemia 
activated the PI3K/Akt pathway and offered cardioprotection (165); however, they reported that 
this protection was less robust than the protection offered by AM administered prior to the 
ischemia period, which was found to offer protection via PKA-dependent activation of 
mitochondrial KCa channels (165). These findings differ slightly from other studies that have 
reported Akt activation with AM administration prior to ischemia (77, 223), however these 
differences might be attributed to the use of different animal models or due to the fact that some 
of these studies performed the ischemia-reperfusion in live animals, while other studies 
performed the ischemia-reperfusion on Langendorff perfused hearts. Overall, these studies 
demonstrate that AM mitigates cardiac damage resulting from ischemia-reperfusion injury 
although the exact mechanism remains a source of debate.  
To date, a limited number of studies have been performed to study the effect of AM 
infusion of cardiovascular disease pathology in human patients (98, 107, 157-159, 166, 228). 
Overall, these studies have found that infusion of AM improves several cardiovascular and renal 
parameters, indicating a potential therapeutic use for AM in the clinic. Hypertension is 
detrimental to overall cardiovascular health as persistent elevations in blood pressure 
necessitate increased force generation by the left ventricle to pump blood to the systemic 
vasculature. This promotes cardiomyocyte hypertrophy to increase to force-generating 
capabilities of the ventricle, allowing for compensation. Eventually, if the pressure remains 
elevated, the cells of the left ventricle fail under the increased workload, resulting in cell death 
and thinning of the ventricular wall and heart failure. Therefore, the reductions in blood pressure 
(98, 107, 159, 166, 228) and systemic vascular resistance (SVR) (158, 159, 166) observed in 
patients with several forms of cardiovascular disease following infusion of AM could offer 
protection by reducing the load on the heart. Cardiac output is a measure of the volume of blood 
pumped by the heart during a specified interval of time and reflects overall cardiac function. 
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With AM infusion, increases in cardiac output were noted in patients with several forms of 
cardiovascular disease, including heart failure (159, 166), essential (228) and pulmonary 
hypertension (158), and myocardial infarction (157), ultimately leading to improved delivery of 
oxygenated blood to the rest of the body for improved patient prognosis. Several studies also 
noted that AM infusion reduced plasma levels of aldosterone (107, 158, 159, 166). Since 
aldosterone acts on the kidney to promote retention of sodium, blood pressure is elevated due 
to increased fluid retention. Therefore, a reduction in circulating aldosterone with AM infusion 
may be beneficial to patients by reducing blood pressure through the secretion of sodium in the 
urine. In fact, one study by Nagaya et al (159) found that AM infusion did indeed increase urine 
production and excretion of sodium supporting the mechanism described above. Finally, in 
patients presenting with acute myocardial infarction, Kataoka et al (98) found that administration 
of AM for 12 hours reduced the size of the infarct, contributing to an increase in wall motion 
within the infarcted area and overall improved cardiac function and patient outcome. Although 
the effect of AM infusion in human patients varied between studies, it is clear that AM can offer 
therapeutic benefits to patients with cardiovascular disease.    
 
Adrenomedullin as a biomarker of human disease 
 Several clinical studies have noted increases in plasma levels of AM above basal levels 
during many human conditions, including: cancer, cardiovascular, renal, pulmonary, and 
autoimmune diseases (97). Given the protective role of AM during cardiovascular disease, 
clinicians have been interested in determining whether circulating levels of AM could be used as 
a novel biomarker of cardiovascular disease severity. However, since the mature form of AM is 
difficult to assess in the plasma due to its instability (146) and affinity for other peptides (184), 
clinical research teams instead assess circulating levels of mid-regional pro-adrenomedullin 
(MR-proAM). Mid-regional pro-adrenomedullin is a stable, 48-amino acid byproduct formed by 
the cleavage of preproadrenomedullin to produce mature AM (101, 212). Since MR-proAM is 
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produced and circulates in the plasma at equal ratios to AM, this stable fragment provides a 
more reliable read-out of plasma AM levels.  
To date, several studies have examined the feasibility of using circulating MR-proAM as 
a biomarker of cardiovascular disease severity (48, 101, 111, 142, 195, 209, 229). In both the 
context of acute myocardial infarction as well as in patients with heart failure following a 
myocardial infarction, circulating plasma levels of MR-proAM were highly associated with 
adverse events (48, 101, 111). These studies also found that MR-proAM alone was a stronger 
biomarker than traditional biomarkers such as BNP (48, 111) and when combined with 
traditional biomarkers, allowed for better stratification of patient risk (101, 142). In addition to 
showing that elevated MR-proAM levels are correlated with increased risk of death in patients 
with coronary artery disease (195), Sabatine et al found that patients with the highest circulating 
levels of MR-proAM benefitted from treatment with trandolapril (195), an angiotensin-converting 
enzyme (ACE) inhibitor used to treat hypertension, unlike patients with lower MR-proAM levels. 
These data reveal that circulating levels of MR-proAM may be useful for identifying patients that 
may benefit from therapeutic interventions, in addition to identifying patients that require more 
intensive monitoring and care. 
Other studies have revealed that the usefulness of AM as a biomarker for adverse 
outcomes is not limited to cardiovascular disease. One such study examined plasma MR-proAM 
levels in patients admitted to the hospital for dyspnea (142). This study found that elevated MR-
proAM was correlated with adverse events not only in patients suffering from acute heart failure, 
but all other patients suffering from dyspnea for any other cause (142). Additionally, Maisel et al 
found that elevated levels of MR-proAM at the time of discharge from the hospital in these 
patients were correlated with poor patient survival in the following three months (142), 
suggesting that high levels of AM at discharge are indicative of underlying problems. A separate 
study performed by Chen et al found that circulating levels of MR-proAM are elevated in 
patients with sepsis, and that patients with the most severe sepsis had the greatest amount of 
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circulating AM (31). Moreover, within each tier of septic severity, patients who died while in the 
hospital consistently had higher levels of AM compared to survivors within the same tier (31), 
highlighting the prognostic value of AM. Finally, work by Seissler et al suggests that MR-proAM 
may be a useful biomarker for metabolic syndrome (202). In this study, plasma levels of MR-
proAM were elevated in patients with metabolic syndrome and type II diabetes (202), although it 
remains to be seen whether this elevation of MR-proAM is indicative of future complications. 
Together, the current literature demonstrates that MR-proAM may prove to be an extremely 
useful biomarker for disease severity in many human conditions. 
 
Polymorphisms of adrenomedullin in human disease 
 In recent years, there has been increased interest in identifying small genomic changes 
that pre-dispose individuals to disease later in life. Single-nucleotide polymorphisms (SNPs) are 
locations within the genome of a species in which a single nucleotide differs between 
individuals. Depending on the location of these SNPs, this alteration of the genetic sequence 
may change the expression of surrounding genes, thereby potentially altering an individual’s 
susceptibility to disease. Given the involvement of AM in many human disease conditions, 
researchers over the past decade have been interested in determining whether SNPs located 
near or within Adm alter disease susceptibility. 
 Some of the earliest studies examining the relationship between AM polymorphisms and 
disease susceptibility were focused on determining whether AM polymorphisms predisposed 
individuals to essential hypertension (90, 112, 199). The first study by Ishimitsu et al focused on 
a microsatellite region of cysteine-arginine (CA) repeats downstream of the Adm gene (90). This 
study found that in a Japanese population, four haplotypes were present, which included 
individuals with 11-, 13-, 14-, or 19-CA repeats in the microsatellite region (90). Ishimitsu et al 
found that individuals with 19-CA repeats were more likely to have essential hypertension, 
however, this alteration in the microsatellite region did not seem to alter expression levels of AM 
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(90), leading the authors to postulate that this change might alter expression of other genes. 
Kobayashi et al also examined the relationship of AM polymorphisms with essential 
hypertension in a Japanese cohort (112). Although Kobayashi et al did not find a correlation 
between AM polymorphisms and risk for essential hypertension, they did find that the A-G-19 
haplotype for SNP rs4399321, SNP rs7944706, and the microsatellite region of Adm was 
correlated with proteinuria in patients with essential hypertension (112). Finally, Sano et al 
examined the relationship between polymorphism in Calcrl, the GPCR that mediates AM 
signaling, and essential hypertension (199). This study found that the T allele for SNP rs696574, 
located in exon 6 of Calcrl, was enriched in women with essential hypertension (199). Although 
it is not clear from this study what impact this polymorphism has on Calcrl expression, this study 
nonetheless adds further support to the conclusion that polymorphism within AM signaling 
system genes may predispose certain individuals to essential hypertension.  
 In addition to the studies testing for associations with essential hypertension (90, 112, 
199), a few studies have been conducted to examine the relationship between AM 
polymorphisms and blood pressure (29, 129). Li et al found that individuals carrying a G allele at 
position -1984 in the Adm promoter, corresponding to SNP rs3814700, had lower pulse 
pressures compared to other individuals (129). This finding may be due to the fact that there 
was a trend for elevated plasma levels of AM in individuals with two copies of the G allele 
compared to other groups, which may be attributed to the creation of a binding site for the 
glucocorticoid receptor in the Adm promoter by this polymorphism (129). A more recent study 
performed by Chen et al revealed that individuals homozygous for the G allele at SNP 
rs4399321 were more likely to have elevated blood pressure compared to individuals with at 
least one copy of the A allele (29). Interestingly, Chen et al found this SNP was even more 
highly correlated with elevated blood pressure in individuals who did not consume alcohol (29), 
although the underlying mechanism behind this finding remains unclear. In summary, these 
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studies demonstrate that polymorphisms in Adm may be correlated with changes in blood 
pressure, although these SNPs may differ between different populations of individuals. 
 Polymorphisms near and within the Adm gene have been correlated with diseases other 
than hypertension, including type II diabetes (91, 174), inflammation (32), and cancer (143). A 
study performed by Ong and colleagues found that individuals with the minor A allele at SNP 
rs11042725 were more likely to develop dysglycemia within six years, indicating development of 
type II diabetes (174). Previous studies using a luciferase assay found that this allele resulted in 
the increased production of AM (69), indicating that elevated plasma levels of AM may be 
contributing directly to the development of dysglycemia and subsequent type II diabetes. A 
separate study performed by Ishimitsu et al found that 19 CA-repeats within the microsatellite 
region of Adm were correlated with the development of renal failure in individuals with pre-
existing type II diabetes, although this polymorphism did not seem to alter levels of AM (91).  
Together, these studies indicate that polymorphisms of Adm may be predictive of type II 
diabetes and resulting renal failure. Inflammation is a common occurrence during many disease 
conditions, and thus, differences in AM levels due to genetic polymorphism may alter the degree 
of inflammation due to the anti-inflammatory properties of AM (37). In support of these findings, 
Cheung et al found that individuals with increasing levels of plasma AM had a significant 
decrease in circulating IL-6 (32), a marker of inflammation. Interestingly, this study also revealed 
that individuals with the minor T allele for SNP rs4910118, located in the 3" un-translated region 
(UTR) of Adm, had a significant reduction in plasma AM (32). Given the importance of AM in 
many disease conditions, this SNP may be a useful marker for identifying patient risk in many 
disease states. Finally, several studies have demonstrated that elevated levels of AM during 
cancer are often detrimental (163). Consistent with these findings, Martínez-Herrero and 
Martínez found the minor T allele of SNP rs4910118 was less prevalent in individuals with 
breast or lung cancer compared to healthy individuals (143). Since the T allele of this SNP is 
correlated with reduced circulating levels of plasma AM (32), it appears that reduced AM may 
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be protective against cancer. Overall, polymorphisms of the Adm gene, diagrammed in Figure 3, 
may be useful markers for identifying individuals at risk for numerous diseases.  
 
Summary 
 In summary, Adm is widely expressed throughout the body from the earliest 
developmental stages through adult life. This widespread expression underscores the 
importance of this peptide not only in modulating proper embryonic development, but also for 
maintaining normal physiology and eliciting responses to disease. As a result of the wide-
ranging effects of AM, it is not surprising that many factors have been shown to regulate Adm 
expression, allowing for fine-tuned control in different scenarios. Several studies have 
demonstrated that plasma levels of AM are elevated during many human disease conditions, 
including cardiovascular disease. This elevation of AM during cardiovascular disease most likely 
serves as a protective mechanism considering that previous studies using animal models have 
revealed that AM is beneficial in many forms of cardiovascular disease. These findings have 
generated interest in examining the usefulness of plasma AM as a biomarker during human 
cardiovascular disease events and have sparked queries investigating whether SNPs within 
Adm alter cardiovascular disease risk. Finally, since AM signals via a pharmacologically-
tractable GPCR-RAMP interface, the AM signaling system pathway may provide a unique 
opportunity to provide therapies for a wide range of human conditions. 
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FIGURE 1.1. Peptide sequences for members of the calcitonin gene-related peptide 
family. 
Amino acid sequences for the members of the calcitonin gene-related peptide (CGRP) family 
are depicted. Each member shares a conserved disulfide bond between cysteine residues, 
forming a ring-like structure. Additionally, biological activity of each peptide is dependent on 
amidation of the C-terminus. Letters depict individual amino acids. 
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FIGURE 1.2. Receptor activity-modifying protein function in AM signaling. 
Interaction of the GPCR calcitonin receptor-like receptor (CLR) with either receptor activity-
modifying protein (RAMP) -2 or -3 results in a receptor for adrenomedullin (AM). However, the 
association of CLR with RAMP1 produces a receptor for calcitonin gene-related peptide 
(CGRP). Unlike the other RAMPs, RAMP3 contains a PDZ domain (depicted as a star in the 
above diagram), which allows for interaction with N-ethylmaleimide Sensitive Factor (NSF) and 
recycling of the receptor complex back to the cell surface. Without the interaction with NSF, the 
RAMP-receptor complex is targeted for degradation in the lysosome. 
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FIGURE 1.3. Single nucleotide polymorphisms located near human Adm gene correlated 
with disease. 
Approximate location of single nucleotide polymorphisms (SNPs) near the human Adm gene 
that have been associated with several human diseases. The major and minor alleles are 
designated above or below each SNP as such: major/minor. 
 19 
CHAPTER II: THE EPICARDIUM DURING CARDIAC DEVELOPMENT AND DISEASE 
Overview
 The epicardium plays a critical role in regulating many aspects of cardiac development. 
Recently, the reactivation of the epicardium during cardiovascular disease has become an area 
of intense interest due to the regenerative and repair possibilities. This chapter provides an 
overview of the formation of the epicardium, as well as the function of the epicardium during 
development and disease.  
 
Origin of the epicardium 
 During the initial stages of cardiac development, the heart consists of two cell layers: the 
myocardium and the endocardium. However, by mid-gestation, a third layer of cells enveloping 
the exterior wall of the heart appears, referred to as the epicardium (Figure 1). Prior to the late 
1970s, whether the epicardium originated from pre-existing cardiac cells or was derived from an 
extracardiac source remained unknown. To address this question, Ho and Shimada (83) used 
scanning electron micrographs to show the migration pattern of epicardial cells over the 
myocardium. These images revealed that epicardial cells originated from mesothelial cells 
located in the sinus venosus (83), eventually termed the proepicardial organ (PEO). Since this 
initial discovery, other groups have corroborated these findings (235), solidifying the PEO as the 
origin of epicardial cells.   
 Although the origin of the epicardium was now clear, the signaling pathways that 
regulate the development of the PEO remained unclear. Work by Watt et al (241) identified the 
transcription factor GATA4 as a critical regulator of PEO formation. This study revealed that a 
loss of GATA4 resulted in severe cardiac defects and embryonic demise between e9.5 and e10. 
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Although GATA4 is expressed in several cell types of the developing heart, including 
cardiomyocytes and the endocardium, Watt et al found that the loss of GATA4 expression in the 
PEO seemed to contribute most profoundly to the observed cardiac defects (241). In particular, 
this study found that the PEO failed to form in embryos lacking GATA4 (241), thereby 
preventing the formation of the epicardium around the heart and contributing to the observed 
cardiac defects. Aside from this initial study, very little work has been done to further elucidate 
the signals required for proper PEO formation. Gaining insight into the underlying mechanisms 
specifying PEO formation from the primitive mesenchyme may provide valuable information 
underlying congenital cardiac defects, making this an important area of future study.  
 In addition to the proper formation of the PEO, proepicardial cells need to migrate from 
the PEO to the heart and adopt an epithelial morphology to initiate the formation of the 
epicardium. Therefore, many groups have focused on determining what signaling pathways play 
a role in regulating these essential processes. Early work performed by Hatcher et al revealed 
that the transcription factor Tbx5 inhibits migration of cells from the PEO to the heart (79), and 
thus, aberrant expression could hinder formation of the epicardium. Furthermore, Jenkins et al 
revealed an important role for retinoic acid X receptor alpha (RXRα) signaling in the outgrowth 
of proepicardial cells (92). In particular, this study found that formation of the epicardium was 
delayed in RXRα-/- animals, due in part to the decreased migration of proepicardial cells towards 
the heart (92), potentially caused by increased fibronectin deposition in the PEO of RXRα-/- 
animals. Additionally, signals from the myocardium also play an important role in directing 
proepicardial cell migration towards the heart. Using chick embryos, Ishii et al (89) determined 
that bone morphogenic protein (BMP) signals, in particular BMP2, from the atrioventricular 
junction on the inner curvature of the developing heart promote proepicardial cell migration from 
the PEO towards the heart. Together, these studies identify several factors important for 
directing proepicardial cell migration, although further studies are necessary to determine many 
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of the downstream factors that are responsible for this process. 
Finally, proepicardial cells must acquire an epithelial phenotype in order to properly 
generate the epicardium. To date, few studies have been conducted to elucidate the factors 
mediating this process. However, one study performed using frog embryos revealed an 
important role for the transcription factor Tcf21 in this process (219). This study found that the 
lack of Tcf21 prevented the maturation of proepicardial cells during the migratory process from 
the PEO towards the heart as indicated by elevated expression of vimentin (219). Additionally, 
proepicardial cells lacking Tcf21 failed to adhere to the heart properly, indicating improper 
maturation (219). Together, these data describe an important role for Tcf21-mediated regulation 
of genes required for the transition from a mesenchymal phenotype to an epithelial phenotype in 
the PEO. However, further studies to identify the downstream targets of Tcf21, as well as 
studies investigating the role of other genes in this transition, are warranted. 
 
Roles of the epicardium during cardiac development 
 Several studies have revealed critical roles for the epicardium in cardiac development. 
Specifically, epicardial cells play an important role in the regulation of cardiomyocyte 
proliferation in the compact zone (120, 128, 180) and also undergo epithelial to mesenchymal 
transition (EMT) to populate the developing heart with fibroblast cells and ensure development 
of the coronary vessels (7, 38, 136, 147, 208, 220). The following paragraphs will delve into 
some of the identified regulators of these processes.  
 Disruption of epicardial formation promotes many cardiac defects, including the 
appearance of a thin compact zone (180). Numerous studies have determined that the 
epicardium regulates the expression of several growth factors, which in turn act on 
cardiomyocytes in the compact zone to promote cell proliferation (120, 128). To date, several 
members of the fibroblast growth factor (FGF) family have been implicated in compact zone 
expansion (120, 180). The earliest of these studies, performed by Pennisi et al in 2003 (180) in 
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chick embryos, identified FGF2 as an important regulator of compact zone cell cycle 
progression. Interestingly, this study found that FGF2 is produced primarily by the 
cardiomyocytes; however the epicardium plays an important role in regulating FGF2 levels 
(180). Although the mechanisms by which the epicardium regulates FGF2 expression in the 
cardiomyocytes were not elucidated in this study, this finding is interesting nonetheless. Work 
performed by Lavine et al (120) demonstrated that epicardial-derived FGF9 promotes 
cardiomyocyte proliferation in the underlying myocardium by acting on the c-splice forms of FGF 
receptor (FGFR)-1 and -2. Furthermore, Lavine et al demonstrated that FGF16 and FGF20, 
which are in the same family as FGF9, are also able to induce cardiomyocyte proliferation 
through the same receptors (120). The results from this study underscore the widespread and 
redundant involvement of FGF signals in the regulation of compact zone proliferation. Recent 
work by Li et al has revealed that growth factors other than the FGFs are produced by the 
epicardium to regulate cardiac development (128). Specifically, this study identified insulin-like 
growth factor (IGF) 2 as an epicardial-derived mitogen that contributes to cardiomyocyte 
proliferation during development (128). This study also revealed that the loss of the IGF 
receptors, specifically IGF1R and INSR, from the cardiomyocytes produced a similar phenotype 
to mice lacking IGF2 (128), indicating that IGF2 secreted from the epicardium acts directly on 
the myocardium to regulate compact zone development. Together, these studies, summarized 
in Figure 2, demonstrate that the epicardium is critical for producing and regulating several 
mitogenic factors to control cardiac development, particularly the proliferation of the 
cardiomyocytes in the compact zone.  
 With the realization that the epicardium produces mitogenic factors, researchers have 
sought to identify upstream factors that control the production of these factors in the epicardium. 
Several groups have demonstrated that retinoic acid signaling is critical for proper cardiac 
development (30, 92, 149). Specifically, these studies have revealed that retinoic acid signaling 
is essential for proper migration of proepicardial cells and for proper formation of the epicardium 
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(92). Additionally, retinoic acid signaling in the epicardium is essential for mediating expression 
of epicardial-derived growth factors and promoting proper proliferation of the cardiomyocytes in 
the compact zone (30, 149). Along these lines, Guadix et al determined that retinaldehyde 
dehydrogenase 2 (RALDH2), which is critical for the synthesis of retinoic acid, is directly 
regulated by the transcription factor, Wt1 (74). Early studies of Wt1 knockout mice revealed that 
this gene plays a critical role in cardiac development, as the loss of Wt1 during embryonic 
development resulted in an overall reduction in heart size and thinned ventricular walls, 
ultimately contributing to embryonic demise between e13.5 and e15.5 (115). Further work 
performed by Moore et al (154) demonstrated that Wt1 expression is restricted to the 
proepicardium and epicardium in the thoracic cavity and that the lack of Wt1 inhibited the 
migration of proepicardial cells towards the heart, resulting in incomplete formation of the 
epicardium. Together, these studies indicate that regulation of retinoic acid signaling is one 
mechanism by which Wt1 modulates cardiac development, as shown in Figure 2.  
  Besides its importance in regulating expansion of the compact zone myocardium, the 
epicardium is also critical for populating the heart with fibroblasts and is an important contributor 
to coronary vessel development (182). These processes rely heavily on the assumption of a 
mesenchymal phenotype by the epicardial cells through EMT. Some of the factors that have 
been implicated in coronary vessel and cardiac fibroblast formation from the epicardium are 
highlighted herein.   
 Given the importance of epicardial EMT in proper cardiac development, several groups 
have sought to define the factors regulating this process. One study found that the growth factor 
platelet-derived growth factor-BB (PDGF-BB) promoted epicardial EMT and resulted in the 
formation of coronary vascular smooth muscle cells (VSMC) (136). This study went on to 
determine that PDGF-BB promoted these effects through rhoA-RhoK-dependent activation of 
serum-response factor (136). Another factor important for regulating the process of EMT in 
epicardial cells is neurofibromin 1 (Nf1) (7). In this study, Baek and Tallquist demonstrated that 
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Nf1 acts to impede EMT in epicardial cells (7). In particular, Baek and Tallquist found that loss 
of Nf1 enhanced ERK signaling and resulted in the premature transition of epicardial cells into a 
mesenchymal lineage (7). Together, these studies provide some insight into the signaling 
pathways regulating the process of epicardial EMT.  
 Invasion of epicardial-derived cells (EPDC) following EMT is an important process for 
the proper formation of the coronary vasculature and cardiac fibroblasts. In addition to its role in 
EMT, Nf1 has also been linked to the invasion of EPDCs (7). Another factor that has been 
implicated in modulating EPDC invasion is Nfatc1 (38). This study found that the loss of Nfatc1 
from the epicardium reduces the extent of migration of both fibroblasts and VSMCs from the 
epicardium into the myocardium (38), potentially attributed to reduced expression of cathepsin 
K, and thus inhibited extracellular matrix degradation. Finally, the transcription factor hypoxia-
inducible factor 1-alpha (HIF-1α) has also been identified as an important factor for regulating 
EPDC invasion (220). Specifically, constitutive over-expression of HIF-1α inhibited migration of 
EPDCs into the myocardium; however, migration into the sub-epicardial space appeared to be 
largely unaffected (220). This study indicates that increased Flt-1 expression, and therefore 
decreased VEGF signaling to the EPDCs, represents one mechanism underlying the impaired 
invasion of EPDCs by HIF-1α (220). These studies highlight the multifaceted regulation of 
EPDC migration and underscore the importance of ensuring proper regulation of this process. 
Additionally, since the epicardium is a hypoxic environment (113), these studies begin to 
examine how the activation of hypoxia-related genes influences cardiac development. 
 Some studies have described how the fate of an EPDC determines which signaling 
pathways are activated to regulate EMT and the subsequent invasion into the myocardium (147, 
208). For example, several studies have highlighted the importance of PDGF signaling in the 
regulation of epicardial EMT and subsequent invasion into the underlying myocardium (7, 136, 
147, 208). However, these studies have demonstrated that PDGF signaling through different 
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PDGF receptor isoforms has different implications on cardiac development. For instance, 
Mellgren et al determined that PDGF signaling via the beta isoform of the PDGF receptor 
(PDGFRβ) is essential for migration of coronary VSMCs derived from the epicardium, although 
EMT does not seem to be altered in this case (147). On the other hand, Smith et al found that 
PDGF signaling through the alpha isoform of the PDGF receptor (PDGFRα) was required for 
the formation and migration of cardiac fibroblasts from the epicardium (208). Although it remains 
to be determined how epicardial cells are assigned a particular fate, these studies identify one 
mechanism by which migration of these EPDC is regulated.  
 Lastly, work by several groups has described the importance of coordinated crosstalk 
between the myocardium and epicardium for the regulation of coronary vascular development. 
Specifically, Lavine et al noted that, in addition to its role in regulating cardiomyocyte 
proliferation (120), FGF9 is crucial for regulating coronary vascular development (119). This 
study found that FGF9 produced by the epicardium acts on the cardiomyocytes to activate sonic 
hedgehog (Shh) signaling in the epicardium through an unidentified mediator (119). Ultimately, 
Shh acts on the myocardium to stimulate VEGF production and release (119). Since studies 
have shown an important role for VEGF in epicardial EMT (161) and coronary vessel 
development (221), activation of these pathways play an important role in proper development 
of the vasculature, as shown in Figure 3.  
 
Potential actions of epicardium during disease 
 After an insult to the heart, several changes occur, including a reversion back towards a 
fetal gene program (191). Normally, the epicardium is quiescent in the adult (206); however, 
several studies have demonstrated that after injury, the epicardium is re-activated (124, 130, 
252) reflecting the shift towards a more fetal phenotype. This reactivation promotes the invasion 
of EPDCs into the injured myocardium to promote revascularization and scar formation. 
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Therefore, the pathways highlighted in the previous section and newly identified pathways may 
play an important role in the response to injury. 
 Cardiac interstitial fibroblasts are largely derived from the epicardium and contribute to 
scar formation after injury. Generally, scar formation is viewed as a detrimental repair process 
that ultimately contributes to declining heart function after injury. However, work by Duan et al 
(52) demonstrates that scar formation is essential for preserving heart function immediately after 
ischemia-reperfusion injury. Specifically, this study reveals that production of cardiac fibroblasts 
by epicardial EMT is essential for maintaining cardiac function in a Wnt/β-catenin-dependent 
fashion (52). In addition to the role of Wnt signaling in scar formation, studies by Russell et al 
(194) have described a role for Notch signaling in activation of the epicardium following injury, 
leading to epicardial EMT and scar formation. Together, these studies describe some of the 
pathways regulating scar formation in adult hearts following injury and may provide insight into 
useful therapeutic targets to obtain an optimal balance between scar formation to preserve heart 
function immediately following injury and preserving long-term cardiac function. 
 Several studies have also suggested that the epicardium may be a source of cardiac 
stem cells. Early studies by Limanan et al (131) determined that a subset of epicardial cells in 
both human and mouse are positive for stem cells markers, including the marker c-kit. Following 
myocardial infarction, the number of cardiac stem cells increased, and these cells were found to 
co-express transcription factors necessary for differentiation into either cardiomyocytes or 
endothelial cells (131). More recent work by Di Meglio et al (49) indicates that the process of 
EMT after injury is able to promote the formation of c-kit-positive stem cells, in addition to other 
cell types. These studies suggest that activation of the epicardium may introduce stem cells in 
the injured myocardium, potentially providing an opportunity to repair the injured heart. 
However, in order to successfully repopulate the heart with cardiomyocytes using resident stem 
cells, several hurdles and remaining questions need to be addressed. For instance, the current 
studies suggest that the number of resident stem cells in the heart is low, and therefore, the 
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number of stem cells produced by the heart needs to be greatly enhanced to facilitate repair. 
Additionally, these stem cells need to be present and activated in the heart after the injury has 
been stabilized by scar formation, which may prove challenging. Finally, the signals promoting 
the preferential formation of cardiomyocytes from the stem cells need to be carefully 
characterized to ensure repopulation of the injured area with viable cardiomyocytes. 
 Finally, some studies have indicated that epicardial-derived cells are capable of 
differentiating into cardiomyocytes (18, 254); however, these findings have been subject to 
debate (33, 182). Although these lineage tracing experiments cannot conclusively determine 
whether epicardial cells may contribute directly to the formation of cardiomyocytes during 
development, there has still been interest in determining whether epicardial-derived cardiac 
progenitor cells in the adult can differentiate into cardiomyocytes following injury to promote 
cardiac repair. Smart et al (207) found that reactivation of the epicardium by thymosin β4 prior to 
injury allowed for the formation of new cardiomyocytes from the activated epicardium. However, 
this result appears to be dependent on the epicardium being reactivated prior to injury, as work 
by Zhou et al (253) found that activation of the epicardium by thymosin β4 after myocardial 
infarction did not promote cardiomyocyte differentiation from the activated epicardium. Thus, in 
the context of human disease, utilizing the activated epicardium to regenerate the damaged 
myocardium may prove to be futile.  
  
Summary 
 In conclusion, many studies have demonstrated a critical role for the epicardium during 
cardiac development. These studies have demonstrated that the epicardium is critical for 
regulating cardiomyocyte proliferation in the compact zone through the production of growth 
factors. Additionally, cells from the epicardium undergo EMT and migrate into the heart to 
populate the heart with interstitial fibroblasts and cover the vessels with smooth muscle. Recent 
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work has suggested that the epicardium plays an important role in the adult heart following 
injury. Given that the adult epicardium is normally quiescent and must be re-activated to a fetal-
like state following injury, a thorough understanding of the factors that regulate epicardial 
function during development is essential for manipulating the epicardium for therapeutic use. 
Finally, whether the epicardium is a source of resident cardiac stem cells needs to be 
investigated further and potentially exploited for repair following myocardial infarction. 
The studies presented in this dissertation explore the role of AM during cardiovascular 
development and disease. The first portion of this dissertation characterizes the effect of AM 
over-expression on cardiac development. This study found that epicardial-derived AM drives 
cardiac hyperplasia during embryogenesis. A second study presented herein investigates sex-
dependent differences in cardiac AM expression and explores the importance of estrogen-
induced microRNAs in balancing Adm expression in female hearts. The final study presented in 
this dissertation begins examining the impact of AM over-expression in the context of chronic 
hypertension by crossing the AM over-expression line to the renin transgenic mouse line. This 
study did not find any differences in disease progression with AM over-expression. However, 
renin transgenic animals with wildtype levels of AM failed to progress as previously described, 
thereby making final interpretation of the effect of AM over-expression on chronic hypertension 
difficult. Overall, these studies further define the role of AM in the cardiovascular system during 
development and provide insight into some potential mechanisms underlying the 
cardioprotective potential of AM during disease. 
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FIGURE 2.1. Schematic of major cardiac structures.  
Cells from the proepicardial organ (PEO), located near the atrio-ventriculatr junction, migrate 
towards the heart beginning around embryonic stage 9.5 (e9.5) in mice. By e10.5, the 
epicardium completely encapsulates the ventricles. Factors produced by the epicardium 
regulate cardiomyocyte proliferation in the compact zone. Additionally, the epicardium is crucial 
for proper coronary vessel development. PEO = proepicardial organ; RA = right atria; LA = left 
atria; PA = pulmonary artery; Ao = aorta; V = valve; RV = right ventricle; LV = left ventricle; 
Endo = endocardium; CV = coronary vessel; TL = trabecular layer; CZ = compact zone; Epi = 
epicardium 
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FIGURE 2.2. Epicardial regulation of cardiomyocyte proliferation during development. 
The epicardium produces and secretes several growth factors, including insulin-like growth 
factor 2 (IGF2) and several members of the fibroblast growth factor (FGF). For members of the 
FGF family, the transcription factor Wilm’s tumor 1 (Wt1) has been shown to increase retinoic 
acid (RA) production and signaling by enhancing transcription of retinaldehyde dehydrogenase 
2 (Raldh2), which ultimately increases FGF transcription. Once secreted from the epicardium, 
these growth factors then act on the appropriate receptor on cardiomyocytes in the compact 
zone to induce proliferation. Fgfr1 = fibroblast growth factor receptor 1; Fgfr2 = fibroblast growth 
factor receptor 2; INSR = insulin receptor; IGF1R = insulin-like growth factor 1 receptor; WT1 = 
Wilm’s tumor 1; Raldh2 = retinaldehyde dehydrogenase 2; RA = retinoic acid; RXR = retinoid X 
receptor; Fgf = fibroblast growth factor; IGF2 = insulin-like growth factor 2   
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FIGURE 2.3. Sonic hedgehog-VEGF pathway crosstalk in coronary vascular 
development. 
Crosstalk between the epicardium and myocardium regulates coronary vasculature 
development by the activation of the sonic hedgehog (Shh) and vascular endothelial growth 
factor (VEGF) pathways. Fgf9 signaling on the myocardium initiates this signaling cascade, 
however the intermediate player of this cascade is currently unknown. Fgf9 = fibroblast growth 
factor 9; Shh = sonic hedgehog; VEGF = vascular endothelial growth factor; FGFr1 = fibroblast 
growth factor receptor 1; Fgfr2 = fibroblast growth factor receptor 2 
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CHAPTER III: EPICARDIAL-DERIVED ADRENOMEDULLIN DRIVES CARDIAC 
HYPERPLASIA DURING EMBRYOGENESIS1 
 
Overview 
 Background:  Growth promoting signals from the epicardium are essential for driving 
myocardial proliferation during embryogenesis.  In adults, these signals become reactivated 
following injury and promote angiogenesis and myocardial repair.  Therefore, identification of 
such paracrine factors could lead to novel therapeutic strategies.  The multi-functional peptide 
adrenomedullin (Adm=gene, AM=protein) is required for normal heart development.  Moreover, 
elevated plasma AM following myocardial infarction offers beneficial cardioprotection and serves 
as a powerful diagnostic and prognostic indication of disease severity.  Results: Here, we 
developed a new model of Adm over-expression by stabilizing the Adm mRNA through gene-
targeted replacement of the endogenous 3’ UTR.  As expected, Admhi/hi mice express three-
times more AM than controls in multiple tissues, including the heart. Despite normal blood 
pressures, Admhi/hi mice unexpectedly showed significantly enlarged hearts due to increased 
cardiac hyperplasia during development. The targeting vector was designed to allow for 
reversion to wildtype levels via Cre-mediated modification.  Using this approach, we 
demonstrate that AM derived from the epicardium, but not the myocardium or cardiac fibroblast, 
is responsible for driving cardiomyocyte hyperplasia.  Conclusions: AM is produced by the 
                                                       
1This chapter previously appeared as an article published in Developmental Dynamics and is 
reprinted with permission. The original citation is as follows: Wetzel-Strong SE, Li M, Klein KR, 
Nishikimi T, and Caron KM. (2014), Epicardial-derived adrenomedullin drives cardiac 
hyperplasia during embryogenesis. Dev Dyn. 243: 243-256. doi: 10.1002/dvdy.24065  
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epicardium and drives myocyte proliferation during development, thus representing a novel and 
clinically-relevant factor potentially related to mechanisms of cardiac repair after injury. 
Introduction  
 Recently, many exciting connections between factors that regulate myocardial 
development and those that are elevated during myocardial injury have been appreciated (46).  
Central to these connections are the unique roles of the epicardium during embryogenesis and 
the newly emerging concept that the epicardium becomes reactivated—re-expressing fetal 
genes—during disease processes (68).  For example, studies in zebrafish and mice have 
shown that the epicardium is required for maintenance of myocardial proliferation during 
embryogenesis through several growth promoting signaling pathways including Raldh2, Wt-1, 
IgF, FGF and b1 integrin (30, 47, 86, 102, 120).  During cardiac injury, many of these same 
growth promoting factors become stimulated such that the potential of the epicardium to 
contribute to heart regeneration and repair is restored from its normally adult quiescent state 
(84, 233).  Several recent studies have begun to elucidate the pleiotropic roles for epicardial-
derived cells (EPDCs) in the formation of numerous cardiac cell types, including coronary 
endothelial and smooth muscle cells, cardiac fibroblasts, heart valves and perhaps even 
cardiomyocytes (46, 68).  However, it is also evident that an important function of the 
epicardium is to secrete paracrine factors that promote angiogenesis, myocardial regeneration 
and cardiac fibroblast proliferation (52, 206).  Therefore identifying new factors that exhibit these 
dual roles of supporting both embryonic and injured heart growth is a desirable and clinically 
promising area of research. 
 In this study, we find that adrenomedullin peptide, secreted from the epicardium, is a 
potent regulator of cardiomyocyte proliferation during embryogenesis.  Since the discovery of 
adrenomedullin (protein = AM, gene = Adm) in 1993 (108), many diverse biological functions 
have been described for this small circulating peptide during development, normal physiology 
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and disease (25, 97).  We, and others, have previously shown that genetic deletion of the highly 
conserved Adm gene in mice causes embryonic lethality at mid-gestation (24, 203, 204).  The 
most prominent phenotype of Adm-/- embryos is their extreme hydrops fetalis, or interstitial 
edema, which we have attributed to a marked arrest of lymphatic endothelial cell proliferation 
and lymphangiogenesis at mid-gestation (59).  However, the expression of Adm, although 
enriched in lymphatic endothelial cells, is not restricted.  Indeed, the earliest and most robust 
expression of Adm can be observed in the heart at around e8.0 (24, 152, 153).  Consequently, 
we found that Adm-/- mice also have small hearts characterized by enhanced trabeculation and 
a thin compact zone (24). Furthermore, loss of either the receptor for AM, calcitonin receptor-
like receptor (Calcrl) (42), or the receptor modifying protein Ramp2 (59) results in a phenocopy 
of the Adm-/- phenotype.  Taken together, the highly conserved and robust cardiac phenotypes 
of mice with genetic deletion of AM signaling components demonstrates the essential function of 
AM in promoting embryonic heart development. 
A multitude of clinical studies have also shown that circulating levels of AM are elevated 
two- to three-fold above basal levels during a variety of human disease conditions (97). 
Recently, the robust surge in plasma AM levels during cardiovascular disease is being used as 
a clinical diagnostic tool. The pro-hormone form of AM, mid regional pro-AM (MRpro-AM), is a 
highly effective clinical biomarker of patient prognosis following heart attack, providing greater 
sensitivity than traditional biomarkers such as atrial natriuretic peptide (ANP) and B-type 
natriuretic peptide (BNP) (48, 141, 142). In addition, AM also offers protection from 
cardiovascular disease.  Several studies using mice haploinsufficient for Adm, have clearly 
demonstrated an exacerbation of cardiovascular disease with a reduction in basal levels of AM 
(20, 203), highlighting the importance of circulating AM in controlling the extent of damage. 
Additionally, animal studies examining the impact of AM infusion on cardiovascular disease 
progression have revealed a protective effect of AM on disease progression (170, 190). 
Furthermore, a limited number of studies performed in human patients have demonstrated that 
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infusion of AM after a cardiovascular incident is associated with a reduction in the degree of 
damage (98, 159, 166). However, since these studies have relied on the infusion of AM, it 
remains unclear whether the physiological 3-fold increase of circulating AM during 
cardiovascular disease has any direct or protective implications. 
Therefore, we sought to develop a mouse model that recapitulates the plasma elevation 
of AM observed during human disease as a useful tool for elucidating the precise functions of 
AM in cardioprotection.  Herein, we describe the successful generation of a novel mouse model 
of Adm over-expression that was intentionally designed to conserve the endogenous promoter 
regulatory elements of the gene, with the added capability of reversing the over-expression by 
Cre-LoxP strategies.  Surprisingly, we discovered that these animals have enlarged hearts due 
to cardiac hyperplasia during development—a phenotype that was reversed when high AM 
levels from the epicardium were genetically restored to basal levels. 
Results 
Transcriptional and translational up-regulation of Adm expression in Admhi/hi mice. 
We recently described the generation of the Admhi/hi mice by gene targeting techniques 
which allowed for the stabilization the Adm mRNA half-life by the bovine growth hormone 3" 
untranslated region (UTR) (126).  Previous in vitro studies predicted that this modification would 
stabilize the mRNA transcript of Adm by approximately 3.5-fold compared to the native 
transcript, while still allowing for endogenous regulation of Adm gene expression by its native 
5"UTR promoter region (93).  Here we show that Adm mRNA transcript levels, as measured by 
quantitative (q)RT-PCR, were statistically increased by approximately 3- to 15-fold in Admhi/hi 
mice compared to wildtype control animals in ten different tissues at 4 months of age (Figure 
1A). Moreover, a radioimmunoassay for total AM peptide levels revealed a statistically 
significant ~3-fold increase in AM peptide levels from kidney and lung extracts (Figure 1B).  
Analysis of circulating AM in the blood plasma of 4 month old animals by a fluorescent EIA 
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method also showed a significant 2- to 3-fold increase in Admhi/hi animals compared to wildtype 
littermates (Figure 1C). Thus, the 3"UTR gene targeting approach successfully recapitulated the 
increases in Adm mRNA and peptide expression at a level that is comparable to that observed 
in human patients with cardiovascular disease and myocardial infarction. 
 
Enhanced Adm expression in developing heart of Admhi/hi mice. 
 Previous studies have shown the developing embryonic mouse heart expresses Adm as 
early as e8.0 and this expression persists throughout development and into adulthood (24, 153).  
Using immunohistochemistry, we find that endogenous levels of AM peptide expression are 
localized to the epicardium, with very low levels of expression in the compact zone and 
trabeculae at e13.5 (Figure 2A,C).  Similarly, Admhi/hi mice showed this same spatiotemporal 
pattern, but as expected, using semi-quantitative imaging, we observed a robust and marked 
increase in AM expression from the epicardium and trabeculae compared to wildtype Adm+/+ 
animals (Figure 2B,D). By assessing the integrated density of AM at the epicardium, we 
confirmed that Admhi/hi embryos express higher levels of AM compared to wildtype controls 
(Figure 2E). We also confirmed that AM is expressed in the epicardium by staining adjacent 
sections for AM and cytokeratin (Figure 2F,G), which has been previously characterized as a 
marker of the epicardium (180, 236). This staining clearly demonstrates that AM is 
predominantly and robustly expressed in the epicardium, and to a much lesser extent in the 
myocardium. Another prominent feature of Admhi/hi hearts that can be appreciated from these 
images is the apparently larger size of the ventricle compared to Adm+/+ hearts viewed at the 
same magnification (compare Figures 2A and 2B). 
 
Admhi/hi mice have enlarged, hyperplastic hearts. 
Unexpectedly, we discovered that 2 month old Admhi/hi mice had remarkably and visibly 
enlarged hearts compared to wildtype controls (Figure 3A).  Heart weight to body weight 
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(HW:BW) ratios (Figure 3B), as well as heart weight to tibia length (HW:TL) ratios (Figure 3C) 
were significantly increased compared to wildtype control mice.  Individual chamber dissections 
revealed that both ventricles and atria of Admhi/hi hearts were significantly enlarged compared to 
those of littermates (Figure 3D).   
 Since either hypertrophic or hyperplastic mechanisms could contribute to enlargement of 
the heart, we used histological techniques to evaluate cardiomyocyte size and density. We 
found no difference in the cardiomyocyte cross-sectional area between wildtype and Admhi/hi 
animals, suggesting that the enlarged hearts of Admhi/hi animals were not hypertrophic (Figure 
4A). This conclusion was further supported by quantitation of cardiomyocyte cellular density 
from wheat germ agglutinin stained sections, which also revealed no difference in cellular 
myocyte density between Admhi/hi animals and wildtype controls (Figure 4B,C). Additionally, 
qRT-PCR analysis of the pro-hypertrophic genes, Anp and Bnp, showed no significant 
differences between wildtype and Admhi/hi animals (Anp expression = 1.20±0.3 versus 1.87±0.3; 
Bnp expression = 1.07±0.2 versus 1.83±0.4 for wildtype and Admhi/hi, respectively), further 
confirming that Admhi/hi hearts are not hypertrophied. Finally, using isolectin staining, we also 
found no significant differences in vascular morphology or density between Admhi/hi animals and 
control animals (Figure 4B,C).  Based on these analyses, it was evident that the Admhi/hi hearts 
were enlarged due to hyperplasia, not hypertrophy—a conclusion that is further supported by 
the fact that Admhi/hi mice do not have elevated blood pressures (Figure 4D). 
 Since Adm expression is prominently enriched in the heart during embryogenesis 
(Figure 2), we performed BrdU incorporation studies to quantitate the number of proliferating 
cells in the hearts of wildtype and Admhi/hi embryos. We assessed proliferation at six different 
time points of embryonic development, and importantly found that Admhi/hi embryos always had 
more BrdU-positive cells per normalized field compared to wildtype, with significant differences 
in five out of six time points (Figure 5A and 5B). From this analysis, it is also interesting to note 
that the shape of the proliferation curve for Admhi/hi animals recapitulates the shape of the curve 
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exhibited by wildtype animals (see Figure 5B), indicating that Admhi/hi hearts are still 
appropriately responding to signals responsible for regulating proliferation rates during 
development. 
To further confirm this developmental hyperplasia, we stained e12.5 hearts with 
phospho-Histone H3 (Figure 5C), a less prevalent proliferation marker, and the cardiomyocyte 
marker, cardiac troponin T (cTnT). Consistent with the BrdU staining, we found a statistically 
significant increase in the level of phospho-Histone H3 labeling in Admhi/hi hearts compared to 
wildtype littermates (Figure 5C).  Moreover, by co-staining with cTnT, we could easily identify 
the phospho-Histone H3-positive cells as cardiomyocytes, by identifying phospho-H3-positive 
nuclei that were surrounded by cTnT signal, as indicated by the asterisks in the 40x images in 
Figure 5C. Finally, we also compared the overall heart size of wildtype and Admhi/hi animals at 
the level of the ventricular valves at e15.5 and as expected, the enhanced levels of proliferation 
in Admhi/hi hearts resulted in a visible enlargement in the heart size of Admhi/hi embryos (Figure 
5D).  
 
High AM drives the cardiomyocyte cell cycle. 
Cyclins and cyclin dependent kinases are critical for maintaining normal cardiomyocyte 
proliferation during development.  Therefore, we further confirmed the accelerated degree of 
proliferation in Admhi/hi hearts by assessing protein levels of cyclin B1 and cyclin D1 by Western 
blotting of postnatal day 1 heart lysates.  Our choice of postnatal day 1 tissue for these assays 
was based on the need to isolate sufficient amounts of protein for Western analysis but 
furthermore allowed us to interrogate whether the hyperplasia of Admhi/hi animals persists 
through the end of the proliferative phase of cardiac development. This analysis revealed a 
significant elevation of both cyclin B1 and cyclin D1 protein in the hearts of Admhi/hi pups 
compared to wildtype (Figure 5E), even during the early postnatal period. As in the late stages 
of embryonic heart development, the proliferation rates in Admhi/hi hearts are modestly, but 
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significantly elevated compared to wildtype animals, further highlighting the responsiveness of 
proliferating cardiomyocytes in Admhi/hi hearts to intrinsic regulators of the cell cycle. 
To determine whether cells in Admhi/hi hearts do indeed exit the cell cycle in a fashion 
comparable to wildtype animals, we also assessed proliferation in the hearts of 6-month old 
adult wildtype and Admhi/hi animals by Ki67 staining. This analysis revealed that levels of 
proliferation are very low in the hearts of both wildtype and Admhi/hi groups, and we found no 
significant difference in the degree of proliferation (data not shown), clearly demonstrating that 
the hyperplasia of Admhi/hi animals is limited to the developmental period.  
We sought to further confirm our in vivo data demonstrating that AM can act directly on 
cardiomyocytes to drive the cell cycle by treating HL-1 cells, a cardiomyocyte cell line, with AM 
peptide. We chose to use the HL-1 cell line since previous studies have demonstrated that 
these cells retain many properties of adult cardiomyocytes in culture, including: cardiomyocyte-
specific currents, gene expression profiles resembling adult cardiomyocytes, and the presence 
of cardiomyocyte-specific structures, such as intercalated discs (36). Additionally, HL-1 cells 
have the ability to proliferate in culture without losing these cardiomyocyte characteristics (36), 
unlike isolated neonatal cardiomyocytes.  Thus, we treated the HL-1 cell line with 1nM AM or 
vehicle in serum-free media and measured cell counts. After 72-hours of treatment, there were 
significantly more HL-1 cells in the AM-treated conditions compared to vehicle–treated cells 
(Figure 5F), indicating that AM can directly drive the proliferation of cardiomyocytes. These 
data, along with our in vivo data, clearly demonstrate first, that AM can act directly on cells to 
drive proliferation, and second, that elevated AM promotes cardiac hyperplasia. 
 
Reversion of the Admhi allele to basal levels reverses the cardiac hyperplasia. 
The design of our targeting vector intentionally included loxP sites flanking the bGH 
3"UTR stabilizing element to allow for tissue- and time-dependent reversion of high Adm levels 
back to wildtype levels (Figure 6A). To confirm that this approach was effective, we crossed the 
 40 
Admhi/+ mice to the CMV-Cre line (201) to generate mice with a wildtype Adm allele, as well as a 
modified Admhi allele, referred to as Adm3’∆.  Adm3’∆ heterozygous mice were then intercrossed, 
at which point the CMV-Cre transgene was selected against, in order to generate homozygous 
Adm3’∆/3’∆ mice.  By qRT-PCR, we found that Adm3’∆/3’∆ mice express Adm at levels comparable 
to wildtype littermates (Figure 6B), confirming that removal of the stabilizing bGH 3"UTR 
element results in a reversion of Adm levels to near basal levels. 
Importantly, this genetic modification also reversed the cardiac hyperplasia phenotype of 
Admhi/hi mice.  At 2 months of age, we assessed the HW:BW ratios of wildtype, Admhi/hi, and 
Adm3’∆/3’∆ mice. We found that Adm3’∆/3’∆ mice had HW:BW ratios that were significantly smaller 
than Admhi/hi mice, and indistinguishable from those of wildtype mice (Figure 6C).  Together, 
these data demonstrate the feasibility of genetically reversing the Admhi allele to normal levels, 
which is also associated with a reversal of the Admhi/hi cardiac hyperplasia phenotype. 
 
AM derived from Wt1-positive cells promotes enhanced heart size of Admhi/hi mice. 
 Our next goal was to use this genetic approach to identify the cellular source of AM that 
drives the observed cardiac hyperplasia during development.  After confirming that we would be 
able to detect a decrease in HW:BW with a global reduction in Adm expression, we proceeded 
to cross the Admhi/hi mice to several different Cre mouse lines to assess the contribution of Adm 
from different cell types within the heart with respect to organ growth. 
We began by assessing the contribution of cardiomyocyte-derived AM because the 
myocardium can release growth factors to regulate heart growth and development (234). 
Therefore, we crossed the Admhi/hi mice to two independent cardiomyocyte-specific Cre lines, 
the Nkx2.5-Cre (156) and αMHC-Cre (3) lines. At 2 months of age, we found there was no 
significant difference in the HW:BW ratio of Admhi/hi and Nkx2.5-Cre+: Adm3’∆/3’∆ mice (Figure 
7A). Additionally, we found no difference in the HW:BW ratio of Admhi/hi and αMHC-Cre+: 
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Adm3’∆/3’∆ mice (data not shown). Together, these two independent cardiomyocyte-specific Cre 
lines clearly indicate that cardiomyocytes are not the cellular source of AM driving the heart 
growth during development. 
Tomoda et al. found that the non-myocyte fraction of the rat heart expressed 
approximately 2.5 times more Adm than the myocyte fraction, suggesting that cardiac 
fibroblasts are a major source of AM in the heart (222).  Therefore, we crossed the Admhi/hi mice 
to the Fsp-Cre (13) mouse line to reduce Adm to wildtype levels in fibroblasts. Once again, we 
found there was no significant difference between Admhi/hi and Fsp-Cre+:Adm3’∆/3’∆ mice at 2 
months of age (Figure 7B), suggesting that cardiac fibroblasts are not a major producer of AM 
during embryonic heart development. 
Finally, we sought to determine whether AM derived from the epicardium contributed 
significantly to heart development because many studies have described the importance of the 
epicardium in secreting paracrine growth factors that regulate heart growth (120, 128, 138), and 
our data demonstrate that the epicardium is a major source of Adm expression during 
embryogenesis (Figure 2). By crossing the Wt1GFPCre/+ (254) mice to the Admhi/hi line, we were 
able to generate mice with reduced Adm in the epicardium (Figure 7D).  In this case, we 
discovered that Wt1GFPCre/+: Adm3’∆/3’∆ mice had HW:BW ratios that were significantly lower that 
Admhi/hi animals, and not significantly different from wildtype animals (Figure 7C). We also 
stained adjacent sections of the left ventricle from these animals for cytokeratin, to mark the 
epicardium, and AM (Figure 7D). We found that AM co-localized with cytokeratin expression in 
the epicardium, further confirming the expression and contribution of epicardial-derived AM in 
heart development. These images also reveal that AM expression of Wt1GFPCre/+:Adm3´∆/3´∆ mice 
is reduced in the epicardium compared to Admhi/hi animals (Figure 7E) and is similar to wildtype 
littermates, thereby verifying that we successfully reduced AM expression in the epicardium of 
these animals, resulting in the normalization of heart size. Finally, to further corroborate these 
findings, we assessed Adm gene expression levels using RNA extracted from 2-month old left 
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ventricle samples from Admhi/hi and Wt1GFPCre/+:Adm3´∆/3´∆ mice. This experiment revealed that 
Adm expression levels are significantly reduced to near baseline values in Wt1GFPCre/+:Adm3´∆/3´∆ 
mice compared to Admhi/hi animals (Figure 7F). Since Cre recombinase is expressed 
specifically in the pro-epicardium and epicardium in the Wt1GFPCre/+ line (254), we concluded that 
a reduction in Adm expression level is due to a normalization of Adm expression levels 
specifically in the epicardium.  Although Adm expression levels were still elevated over wildtype 
levels in Wt1GFPCre/+:Adm3´∆/3´∆ animals, it is important to recognize that this difference can be 
attributed to the fact that other cell types in the heart, including cardiomyocytes and fibroblasts, 
are still over-expressing Adm. Since we have demonstrated that a reduction of Adm levels in 
cardiomyocytes and fibroblasts fails to affect the HW:BW ratios (Figure 7A and 7B), these data 
indicate that the epicardium is a major source of Adm that promotes cardiac hyperplasia in the 
Admhi/hi line. 
Discussion 
With this unique gene targeted mouse model, we have identified AM as a powerful 
regulator of cardiac growth during embryogenesis.  Importantly, we have been able to 
demonstrate that AM secreted from epicardial cells is important for driving the cardiomyocyte 
cell cycle and promoting enlargement of the heart during embryogenesis.  Considering the 
numerous and high profile clinical studies which link elevated plasma AM levels following 
myocardial infarction with both disease severity and cardioprotection, we consider that AM 
fulfills the characteristics of a newly recognized epicardial-derived growth factor that may play 
important roles in cardiac repair and regeneration. 
Most importantly, the pharmacological targeting of AM signaling is readily achievable 
through small molecule agonists and antagonists capable of binding to the unique interface 
formed between the AM receptor, calcitonin receptor-like receptor and receptor activity 
modifying protein (RAMP) 2 (5).  Indeed this receptor- RAMP paradigm is already being 
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exploited by the pharmaceutical industry for the treatment of migraine pain associated with 
CGRP signaling (50, 198).  Therefore, while the delivery of AM peptide has some limitations as 
a treatment strategy for myocardial infarction, activation of AM signaling through its unique G 
protein-coupled receptor paradigm is attainable. 
 In the literature, a limited number of mouse models have been reported that display 
cardiac hyperplasia (27, 81, 100, 183, 188, 227). Many of these mutant animals die during the 
late embryonic development or the early postnatal period (81, 100, 183, 188), which contrasts 
with this Admhi/hi model, which survives into adulthood. This difference can, perhaps, be 
attributed to the presence of additional cardiac defects in some lines or differences in how the 
heart is enlarged. For example, many of these mouse lines display other cardiac abnormalities 
in addition to cardiomyocyte hyperplasia, including: ventricular septal defects (81, 100, 183), 
double outlet right ventricles (100), and dilated atria (183, 188). The Admhi/hi mice do not display 
additional cardiac defects, which potentially explains why these mice are viable.  Moreover, 
several of the other reported mouse lines displaying cardiac hyperplasia display a reduction in 
the luminal space of the ventricle due to a robust increase in the space occupied by the 
trabeculi as well as a drastic increase in the thickness of the compact layer (81, 100, 183, 188). 
Since the degree of trabeculation between wildtype and Admhi/hi animals appears similar, the 
lumens of the Admhi/hi mice remain unobstructed, allowing for normal heart function and viability 
of the mice. 
 We found that a reduction of Adm in the epicardium through the use of the Wt1GFPCre/+ 
mouse line resulted in a reversion of the HW:BW ratio back to wildtype levels, indicating that the 
cardiac hyperplasia phenotype of the Admhi/hi mice is caused by enhanced epicardial-derived 
AM. Some studies have indicated that Wt1 is expressed in a subset of cardiomyocytes during 
embryonic development (193), and therefore, the Wt1GFPCre/+ line may promote recombination 
directly in the cardiomyocytes. Additionally, other groups have suggested that epicardial cells 
may differentiate into cardiomyocytes (18, 254), and thus the recombined genes from the cross 
 44 
to the Wt1GFPCre/+ line may be transmitted to the cardiomyocyte lineage. Therefore, it is possible 
that additional recombination in cardiomyocytes through one of these two mechanisms is 
contributing to the reduction of the HW:BW ratio in Wt1GFPCre/+:Adm3´∆/3´∆ mice. However, our 
data from two independent cardiomyocyte-specific Cre lines showing no reduction in HW:BW 
with reduced levels of AM expression in cardiomyocytes suggests that the contribution of 
cardiomyocyte-derived AM to the developmental hyperplasia observed in the Admhi/hi line is 
minimal. 
Our conclusion that the epicardium is a major contributor of AM during heart 
development is further supported by the similarities between the heart phenotype of Adm-/- mice 
(24) and animals with a disrupted epicardium (115, 117, 128, 180). Specifically, one 
characteristic of animals lacking an epicardium or with disrupted growth factor secretion from 
the epicardium is a thin compact zone (115, 117, 128, 180), which was also observed in the 
Adm-/- mice (24). Although Adm-/- animals do not exhibit other cardiac defects that are 
sometimes described in other models with epicardial alterations, it is possible that AM acts 
independently or through different growth factors than those investigated to date. Additionally, it 
is possible that AM may play a role in the endocardium, as Adm-/- embryos also have abnormal 
trabeculation compared to wildtype littermates (24), and the endocardium has been implicated 
in the regulation of trabecular development (65, 72, 123, 150, 210). However, since the majority 
of the proliferation we observed in the hearts of Admhi/hi hearts was localized to the compact 
zone and septum (see Figure 5C) and the development of these areas is largely regulated by 
the epicardium (67, 214), it seems likely that endocardial-derived AM contributes minimally to 
the observed cardiac hyperplasia.  
Our current study does not excluded the possibility that AM may interact with other 
growth factors to promote cardiac hyperplasia in Admhi/hi animals. To date, several epicardial-
derived factors critical to compact zone proliferation have been identified. These factors include 
several members of the fibroblast growth factor (FGF) family (120), members of the insulin 
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growth factor (IGF) signaling cascade (128), as well as retinoic acid (RA) (28, 30, 149, 213) and 
erythropoietin (Epo) (213, 248). Presently, it remains unclear whether any interaction exists 
between AM and these factors in the heart to promote the cardiac hyperplasia observed in 
Admhi/hi animals. Similar to AM, the FGFs and their corresponding receptors are widely 
expressed throughout the body during development and play an important role in regulating 
cellular growth in many organ systems (122). Although there have been very few studies 
investigating any relationship between AM and the FGFs, one recent study found that 
transgenic over-expression of FGF18 in the lung during the early postnatal development period 
promoted an increase in Adm expression (58), indicating the potential for crosstalk between 
these two signaling pathways; however, it is unknown whether a similar paradigm exists in the 
heart during embryonic development. Another potential mechanism by which the Adm signaling 
pathway may interact with other epicardial-derived signals is through the transactivation of FGF 
and IGF receptors. Guidolin et al. (75) have reported that AM may transactivate the VEGFR2 to 
promote angiogenesis in human vascular endothelial cells. Specifically, they found that the 
angiogenic properties of AM were dependent on the tyrosine kinase domain of the VEGFR2 
receptor, (75) which suggests that other receptor tyrosine kinases, such as the FGF and IGF 
receptors, may be subject to transactivation by AM signaling. Furthermore, Cornish et al. (40) 
found that AM-induced proliferation of osteoblasts was inhibited with the loss of IGF-1R, 
indicating a potentially broader paradigm for crosstalk between AM signaling and receptor 
tyrosine kinases. Finally, several studies have demonstrated that Epo and RA are essential 
regulators of epicardial-derived growth factors (28, 30, 149, 213, 248). Although there is no data 
currently available that demonstrates a direct relationship between AM and Epo, both of these 
peptides are strongly induced by hypoxia through HIF-1α (54, 64), which may indicate parallel 
function. Finally, a limited number of studies have examined the relationship between AM and 
RA (116, 151). These studies have found that in macrophages (116) and vascular smooth 
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muscle cells (151), RA induced Adm expression, indicating that Adm may be induced by RA in 
the epicardium during cardiac development to regulate cardiomyocyte proliferation.  
 Future studies to elucidate these interactions are underway.  For example, this Adm 
over-expression model will be useful for understanding the importance of AM elevation during 
disease, and with Cre-recombinase technology, we can begin to address in what tissues and at 
what times AM elevation is advantageous. Additionally, the role of AM during developmental 
processes of many organs, including the heart, lymphatic system, and other organ systems, can 
be studied more thoroughly due to the viability of these animals. 
Experimental Procedures 
Animals 
Admhi/hi mice were generated using standard gene targeting techniques, as described in 
detail in (126).  Briefly, the targeting vector was designed to replace the endogenous 3" 
untranslated region (UTR) with a stabilizing cassette that increases the Adm mRNA half-life.  
Additionally, loxP sites allow for the deletion of the stabilizing element and its replacement by an 
80 bp of AU/U-rich element of the mouse c-fos gene (ARE) (Figure 6A).  For genotyping, a 3-
primer, PCR-based strategy was used: primer 1: 5′- AACCTTACACCTTGCTGAGACATTC-3′; 
primer 2: 5′- TTTATTAGGAAAGGACAGTGGGAGTG-3′; primer 3: 5′-
CCCACATTCGTGTCAAACGCTAC-3′. Primers 1 and 3 amplify a 760-bp wildtype allele, while 
primers 2 and 3 amplify a 600-bp targeted allele. Mice used in these studies were either from a 
mixed genetic background or backcrossed to the C57Bl6 strain for over 9 generations.  For all 
experiments, littermate animals were used as controls.  
 To generate mice with reduced Adm expression either globally or in specific cells types, 
Admhi/hi mice were crossed with the following previously characterized Cre mouse lines: CMV-
Cre (201), αMHC-Cre (3), Nkx2.5-Cre (156), Fsp-Cre (13), or Wt1GFPCre/+ (254).  The 
recombined Admhi allele was designated Adm3’∆.  Heart weight to body weight (HW:BW) ratios 
 47 
were assessed at 2 months of age. All studies were approved by the Institutional Animal Care 
and Use Committee of UNC-CH. 
Gene expression analysis   
Adm gene expression was analyzed by quantitative (q)RT-PCR with the Mx3000P Real-
Time PCR System from Stratagene. Primers for Adm amplification were 5′-
GAGCGAAGCCCACATTCGT-3′ and 5′-GAAGCGGCATCCATTGCT-3′ and the probe sequence 
was 5′-FAM-CTACCGCCAGAGCATGAACCAGGG-TAMRA-3′. Primers for Bnp amplification 
were 5′-CTGCTGGAGCTGATAAGAGA-3" and 5′-TGCCCAAAGCAGCTTGAGAT-3′ and the 
probe sequence was 5′-FAM-CTCAAGGCAGCACCCTCCGGG-TAMRA-3′. Taqman Gene 
Expression Assays for Anp and GAPDH were purchased from Applied Biosystems. Embryonic 
lung RNA from Ambion was used as calibrator. RNA was isolated from mouse tissues with 
Trizol and subsequently DNaseI treated. The ∆∆Ct method was used to determine the relative 
levels of gene expression. Assays were repeated 3 times, each time with triplicates. 
Measurement of AM peptide   
Mouse AM was measured using a specific immunoradiometric assay kit (AM RIA, 
Shionogi) with some modifications, as previously reported (167, 169). Plasma levels of AM were 
measured by a fluorescent immunoassay (Phoenix Pharmaceuticals, FEK-010-08) following the 
manufacturer’s protocol. 
Adrenomedullin staining   
Paraffin embedded left ventricle sections were blocked for 1 hour in 5% normal donkey 
serum at room temperature. Slides were then incubated with adrenomedullin antibody (Novus, 
NBP1-19731) overnight at room temperature. Slides were washed with PBS prior to incubation 
with secondary antibodies for 2 hours at room temperature. 
Cytokeratin staining   
Paraffin embedded tissues were subjected to three, 5 minute rounds of antigen retrieval 
in 10mM citric acid buffer/0.05% Tween 20. Slides were then blocked in 5% normal donkey 
 48 
serum/0.1% Triton X at room temperature for 1 hour. Slides were incubated with diluted 
cytokeratin primary antibody (Dako, Z0622) overnight at room temperature. After washing slides 
with PBS, secondary antibody was applied for 2 hours at room temperature in the dark. 
Capillary density and cardiomyocyte density assay   
Paraffin embedded heart sections were blocked in 1%BSA/0.2% triton X-100 in PBS for 
one hour, then incubated with Isolectin B4 FITC conjugate (Sigma L2895, 1:200), Rhodamine 
wheat germ agglutinin (Vector Laboratories, RL-1022, 1:1000), and 1:1000 DAPI in 1%BSA in 
PBS for 2.5 hours at room temperature, then washed in PBS and rinsed with ddH2O. 
Measurement of mean arterial pressure (MAP)  
The MAP was assessed by the tail cuff method as previously described (114). Briefly, 
mice were acclimated to the restraint apparatus for two days prior to data collection. For three 
days following the acclimation period, blood pressure data were collected for each mouse. The 
data from the three days were then averaged together to generate the MAP value.  
BrdU incorporation assay   
Timed matings were performed between Admhi/+ males and females. Two hours prior to 
the dissection of the embryos, the pregnant female was injected with BrdU (0.1mg/g of BW) via 
tail vein injection. Embryos were carefully dissected and genotypes were determined from DNA 
extracted from either the yolk sac or the tail. Frozen sections of the heart were stained for BrdU 
using a diaminobenzidine (DAB)-based protocol. 
Phospho-Histone H3 (Ser10) and cardiac troponin co-staining  
Frozen e12.5 embryo heart sections were thawed overnight prior to antigen retrieval. 
Slides were blocked in 10% normal goat serum in 0.05M Tris buffer for 1 hour prior to applying 
primary phospho-Histone H3 antibody (Cell Signaling, 9701) and cardiac troponin T antibody 
(Thermo, MS-295-P) to slides overnight at 4°C. Slides were washed with three changes of 
0.05M Tris buffer prior to incubating with fluorescent secondary antibody for 2 hours at room 
temperature in the dark. 
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Cyclin B1 and cyclin D1 Western blot   
Hearts were dissected from postnatal day 1 pups and flash-frozen in liquid nitrogen. 
Protein was isolated from wildtype and Admhi/hi hearts using standard procedures. Samples 
were denatured and run on NuPage Bis-Tris gels and proteins were transferred to PVDF 
membranes. Membranes were probed with cyclin B1 (Rockland, 100-401-152), cyclin D1 
(Rockland, 100-401-153) and actin (Sigma, A4700) antibodies overnight at 4ºC. Membranes 
were incubated with secondary antibodies for 45minutes and imaged using a Li-Cor Odyssey 
CLx. Integrated density was assessed using ImageJ software. 
Proliferation of HL-1 cells with AM treatment   
HL-1 cells are a cardiomyocyte cell line first developed and characterized by Claycomb 
et al. in 1998 (36). When cultured in Claycomb media (Sigma, 51800C), supplemented with 
norepinephrine and L-glutamine, these cells retain many properties of cardiomyocytes, but, 
unlike isolated cardiomyocytes, will proliferate in culture (36). For this experiment, HL-1 cells 
were plated in fibronectin/gelatin-coated 24-well dishes at a density of 50,000 cells per well in 
serum-free media. Cells were allowed to adhere to the plates for 4 hours prior to treatment. At 
the time of treatment, the media was removed from each well and replaced with serum-free 
media containing either tissue culture-grade water as a vehicle control or 1nM AM (Phoenix 
Pharmaceuticals, 010-31). Total cell numbers in each well were counted using a Countess 
Automated Cell Counter. Each condition was performed in triplicate to allow for statistical 
analysis. 
Statistics   
Statistical analyses were performed with JMP software (SAS). One-way ANOVA was 
used to determine significance at p < 0.05. In all figures, error bars represent SEM. 
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Figures 
 
 
FIGURE 3.1. Transcriptional and translational up-regulation of Adm.  
A. Quantitative RT-PCR analysis of Adm from wildtype and Admhi/hi tissues (n = 3-10) at 4 
months of age. B. Peptide levels of AM from 2- to 3-month old wildtype and Admhi/hi lung and 
kidney as determined by a radioimmunoassay (n = 5-6). C. Plasma levels of AM from 4-month 
old wildtype and Admhi/hi animals using a fluorescent immunoassay (n = 3). All values are ± 
SEM. *p<0.05, **p<0.01, ***p<0.001 
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FIGURE 3.2.  AM expression is localized to the developing epicardium and up-regulated 
in Admhi/hi mice.  
Immunofluorescence of AM peptide in heart sections of e13.5 embryos.  A. and C. Adm+/+ 
control mice.  B. and D. Admhi/hi mice.  Images A & B were obtained with a 300 msec exposure, 
while images C and D were obtained with a 75 msec exposure.  Boxes in A and B represent 
fields shown in panels C and D, respectively. E. The amount of AM expressed in the epicardium 
was assessed from panels C and D by measuring the integrated density of staining using Image 
J software. Data are expressed as arbitrary units (AU) of integrated density. Colocalization of 
AM peptide and the epicardial marker, cytokeratin. F. and H. Adrenomedullin staining. G. and I. 
cytokeratin staining. The white boxes on panels F and G indicate the fields presented in panels 
H and I, respectively. Filled arrow heads on panels F and H indicate areas of AM staining, while 
open arrow heads in panels G and I highlight areas positive for cytokeratin staining. TR = 
trabecular zone; CZ = compact zone. Scale bars = 50 mM.  All values are ± SEM.  **p<0.01 
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FIGURE 3.3. Admhi/hi mice have larger hearts that wildtype littermates  
A. Gross appearance of hearts from 9-week old male wildtype and Admhi/hi mice. B. Heart 
weight to body weight (HW:BW) ratios were assessed at 2 months of age (n = 6-12). C. Heart 
weight to tibia length (HW:TL) ratios were assessed at 2-4 months of age (n = 6). D. The ratio of 
left ventricle (LV), right ventricle (RV), left atria (LA), and right atria (RA) to body weight was 
assessed at 2 months of age to obtain chamber weight to body weight (CW:BW) ratios (n = 6-
11). All values are ± SEM. *p<0.05, **p<0.01, ***p<0.001 
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FIGURE 3.4. Hearts of Admhi/hi mice are not hypertrophic.  
A. Representative heart sections were stained with hematoxylin and eosin (H&E). The 
cardiomyocyte cross-sectional area was determined from 15 individual myocytes per animal 
(n=3). B. Representative heart sections were stained with isolectin (green), wheat germ 
agglutinin (WGA) (red), and DAPI (blue). We have also included single channel views of the 
WGA and isolectin staining to aid in the visualization of the vascular and cellular density. C. 
Total numbers of vessels and cardiomyocytes were quantitated from images at 20x 
magnification (n = 3-8). Data shown here are representative of two independent experiments 
conducted by separate researchers. D. Mean arterial pressure (MAP) measurements assessed 
by tail cuff (n = 3-4). All values are ± SEM. 
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FIGURE 3.5. Enhanced proliferation of Admhi/hi hearts during embryonic development.  
A. Representative images of wildtype and Admhi/hi hearts at embryonic day e12.5 stained for 
BrdU. B. Quantitation of the total number of BrdU positive cells from wildtype and Admhi/hi hearts 
throughout embryonic development normalized to the number of pixels in the image that were 
analyzed. C. Representative images of wildtype and Admhi/hi hearts at embryonic day e12.5 
stained with phospho-Histone H3 (p-Histone H3) (green), cardiac troponin T (cTnT) (red), and 
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DAPI (blue). The white boxes on the 4x (upper panels) and 20x (middle panels) images 
represent the areas magnified in the 20x and 40x (lower panels) images, respectively. Asterisks 
on 40x images indicate proliferating cardiomyocytes. The graph in the lower panel shows the 
number of phospho-Histone H3-positive cells per cardiomyocyte, which was determined by 
assessing three 20x magnification fields per animal (n=3). D. Low-power images of e15.5 
wildtype and Admhi/hi hearts showing differences in heart size. Scale bar = 100µm E. 
Representative Western blot for cyclin B1 and cyclin D1 normalized to actin. Each lane on the 
blot is loaded with protein lysates from individual postnatal day 1 pups. Differences in lane 
loading were accounted for by normalizing each cyclin band to the corresponding actin band for 
each lane. These numbers were then normalized to a wildtype sample to compute the fold 
change. F. Proliferation of the HL-1 cardiomyocyte cell line with AM treatment. HL-1 cells were 
treated in serum-free media for 72 hours with either vehicle or 1nM AM, prior to performing cell 
counts. Each condition was performed in triplicate. All values represent means ± SEM. *p<0.05, 
**p<0.01, ***p<0.001 
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FIGURE 3.6. Mice with excised bGH 3"UTR have normal-sized hearts.  
A. Gene targeting design indicating the location of loxP sites flanking the bovine growth 
hormone (bGH) 3"UTR segment. B. Admhi/+ mice were bred to the CMV-Cre line to globally 
excise the bGH 3"UTR fragment from the Admhi allele. This new allele is designated as Adm3´∆. 
After removing the Cre recombinase via breeding, Adm expression was assessed by qRT-PCR 
(n = 5-6). C. At 2-3 months of age, the heart weight to body weight (HW:BW) ratios of Adm3´∆/3´∆ 
mice was compared to the HW:BW ratios of age-matched Admhi/hi and wildtype mice (n = 5-7). 
All values represent means ± SEM. *p<0.05, **p<0.01, ***p<0.001 
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FIGURE 3.7. Epicardial-derived AM contributes to cardiac hyperplasia of Admhi/hi mice.  
A. Admhi/hi mice were crossed with the Nkx2.5-Cre mouse line to generate Admhi/hi animals with 
wildtype levels of Adm in cardiomyocytes. Heart weight to body weight (HW:BW) ratios were 
assessed at 2 months of age (n = 4-8). B. Admhi/hi mice were crossed to the Fsp-Cre mouse line 
to generate Admhi/hi mice with wildtype levels of Adm in fibroblasts. Heart weight to body weight 
(HW:BW) ratios were assessed at 2 months of age (n = 4-10). C. Admhi/hi mice were crossed 
with the Wt1GFPCre/+ mouse line to generate Admhi/hi mice with wildtype levels of Adm in the 
epicardium. At 2 months of age, heart weight to body weight (HW:BW) ratios were assessed (n 
= 3-6). D. Adjacent left ventricle sections from wildtype, Admhi/hi, and Wt1GFPCre/+:Adm3´∆/3´∆ mice 
were stained with adrenomedullin (left panels) and the epicardial marker, cytokeratin (right 
panels). Adrenomedullin and cytokeratin images were acquired with a 130 msec exposure for all 
images. Images were acquired at 20x magnification and the scale bar represents 50µm. E. The 
amount of AM expressed in the epicardium was assessed from the images in panel D by 
measuring the integrated density using Image J software. The data are presented as arbitrary 
units (AU) of integrated density. F. RNA extracted from 2-month old left ventricle samples was 
used to assess the relative expression levels of Adm by qRT-PCR. All values represent means 
± SEM. *p<0.05, **p<0.01, ***p<0.001
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CHAPTER IV: COHORT OF ESTROGEN-INDUCED MICRORNAS, INCLUDING THE NOVEL 
MIR-879, BALANCE ADRENOMEDULLIN EXPRESSION IN RESPONSE TO ESTROGEN 
SIGNALING2 
 
Overview 
 
 Estrogen regulates the expression of many genes and has been correlated with 
differences in cardiac contraction; however the underlying mechanisms remain poorly defined. 
Adrenomedullin (Adm = gene; AM = protein) is a multi-functional peptide with inotropic actions. 
Previous studies have demonstrated that Adm expression is increased in the presence of 
estrogen, suggesting a relationship between AM and estrogen in cardiac contraction during 
physiological and pathological states. In this study, female mice in a mouse model of genetic 
Adm over-expression, referred to as Admhi/hi mice, were found to express 60-times more Adm in 
the heart than wildtype littermates, which was greater than the 3-fold elevation of Adm observed 
in Admhi/hi male hearts. This drastic elevation of Adm was correlated with an enhancement of 
cardiac function. Interestingly, ovariectomy reversed the dramatic over-expression of Adm and 
resulted in a reversion of heart function to wildtype levels. Since the 3" untranslated region 
(UTR) of Adm was displaced to generate the Admhi/hi line, the theory that estrogen-induced 
microRNAs normally down-regulate Adm levels in an estrogen-dependent fashion to prevent 
aberrant Adm over-expression in females was examined. Using a bioinformatic approach, it was 
determined that the mouse Adm 3´UTR contains many target sites for previously characterized 
estrogen-induced microRNAs. This study also determined that the novel microRNA, miR-879, is 
                                                       
2This work is currently in revision for publication in The American Journal of Physiology – 
Regulatory, Integrative and Comparative Physiology. Permission for re-printing will be obtained 
upon publication. Contributing authors include: Sarah E. Wetzel-Strong, Manyu Li, Scott T. 
Espenschied, and Kathleen M. Caron 
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another estrogen-induced microRNA that does in fact interact with the 3´UTR of Adm to 
destabilize the mRNA. Together, these studies revealed that estrogen-induced microRNAs play 
an important role in balancing Adm expression in females.   
 
Introduction 
 
 The steroid hormone 17β-estradiol, referred to herein as estrogen, plays an important 
role in the regulation of gene transcription. Several mechanisms have been described by which 
estrogen can regulate gene expression. In the classical model of estrogen signaling, estrogen 
interacts with cytoplasmic estrogen receptor-alpha (ERα) or ER-beta (ERβ), resulting in 
translocation of the estrogen-ER complex to the nucleus (14). Once in the nucleus, the 
estrogen-ER complex can either interact directly with the DNA at estrogen response elements 
(ERE) (176) or the complex can interact with other transcription factors to indirectly regulate 
transcription (164, 242). Additionally, estrogen receptors bound to the plasma membrane can 
promote downstream signaling when activated by estrogen (179). Moreover, phosphorylation of 
estrogen receptors can result in ligand-independent activation and subsequent gene expression 
regulation (225). Finally, estrogen can interact with G protein-coupled estrogen receptor 1 
(GPER), resulting in activation of downstream signaling and subsequent gene expression 
changes (56). Together, the multitude of pathways by which estrogen can influence cellular 
functions and gene transcription underscores the complexity of estrogen-mediated actions in 
physiological and pathological states. 
For many years, researchers have recognized that differences exist between males and 
females with regards to cardiac function both in physiological and pathological scenarios (34, 
62, 82, 135, 178). For instance, several studies have noted that healthy females have higher 
ejection fractions compared to age-matched males (34, 178). Interestingly, several studies have 
demonstrated that women are more likely to have heart failure with preserved ejection fraction 
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than men (62, 82), suggesting a role for female sex hormones in systolic heart function. In 
addition to the effect of female sex hormones on ejection fraction, work by Locati et al revealed 
that females are at increased risk for long QT syndrome (135), indicating that sex hormones 
might contribute to disease pathology. Animal studies have demonstrated that sex hormones, 
and in particular estrogen, can directly promote an increase in the QT interval (51, 196), 
confirming the sex-dependent differences observed in humans. Together, these findings, along 
with studies demonstrating that ERα and ERβ are expressed in endothelial cells (55), smooth 
muscle cells (192), cardiomyocytes and fibroblasts (73), underscore a widespread role for 
female sex hormones in the regulation of cardiac contraction. 
Cardiomyocyte contraction is dependent on the generation of an action potential, which 
is regulated by the flow of ions between the cardiomyocyte and the extracellular space through 
ion channels. Thus, disruptions in normal ion flow, either by altered levels of the ion channels or 
mutations in the ion channel components, can impact cardiomyocyte contraction and heart 
function. In animal models of long QT syndrome, estrogen was found to decrease the levels of 
several potassium channels in the heart (51, 196), leading to the lengthening of the QT interval 
and arrhythmias. In humans, many ion channels in the heart are differentially regulated with sex, 
including the down-regulation of several potassium channels in the female heart (61). Together, 
these studies highlight the sex-dependent differences in cardiac function, mediated in part by 
differences in ion channel expression. Undoubtedly, a further understanding of the effects of 
estrogen on the cardiovascular system is necessary for developing effective therapeutics for 
women.  
 Recently, several groups have demonstrated that estrogen can regulate the expression 
of microRNAs (12, 26, 35, 172, 177). These short DNA fragments work primarily to repress 
gene expression by interacting with the 3´ untranslated region (3´UTR) to either prevent 
translation of the mRNA into protein or to promote degradation of the mRNA (11). Due to the 
tendency for families of microRNAs to target multiple genes within a particular network (148), 
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there has been a surge in interest regarding the role of microRNAs during cardiovascular 
disease, since therapies may be more effective if multiple components of a pathway can be 
targeted at one time.   
 Adrenomedullin (Adm = gene; AM = protein) is a secreted peptide with a multitude of 
functions (19, 24, 37, 87, 106, 108, 168, 231). Specifically in the heart, several groups have 
described an inotropic role for AM (87, 216, 217), although these findings have been 
controversial (88, 211). During many human disease conditions, including cardiovascular 
disease, circulating levels of AM in the plasma are significantly elevated above baseline levels 
(97). Thus, the inotropic role of AM (87, 216, 217), along with other cardioprotective properties 
(8, 20, 203), indicate that the observed elevation of AM in the plasma during cardiovascular 
disease most likely serves to mitigate the extent of damage. Interestingly, Adm expression is 
enhanced by estrogen through ERα-dependent mechanisms (240), indicating that AM signaling 
may represent a novel mechanism by which estrogen protects the hearts of females. In this 
study, the serendipitous discovery of drastic Adm over-expression in the heart of female Admhi/hi 
mice was explored. Specifically, since the native Adm 3"UTR was displaced with the generation 
of the Admhi/hi line, the possibility of estrogen-dependent negative regulation of Adm at the 
3"UTR was examined.  
 
Materials and Methods 
 
Mice 
The generation of Admhi/hi mice has been documented previously (126, 245). Briefly, 
gene targeting techniques were used to insert the bovine growth hormone (bGH) 3´UTR 
upstream of the native Adm 3´UTR, thereby stabilizing the Adm mRNA. Mice used in these 
studies were either from a mixed genetic background (129S6/SvEv x C57Bl6/J) or backcrossed 
to the C57Bl6/J strain for over 9 generations.  For all experiments, littermate animals were used 
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as controls. To assess the impact of endogenous estrogen on expression levels of Adm 
wildtype animals from the 129S6/SvEv background, referred to as SvEV, were utilized. 
Ovariectomized C57Bl6/J females and intact controls during estrus and diestrus were used to 
assess the impact of endogenous estrogen on expression of Eig121l and miR-879.   
Ovariectomy was performed to remove the influence of endogenous hormones on gene 
expression. Mice were 21- to 28-days old at the time of ovariectomy. Mice were anesthetized 
with avertin (400-500 mg/kg/body weight) and placed on a warm heating pad to maintain body 
temperature throughout the surgical procedure. Hair was removed from the abdomen and a 
small <1 cm incision was made through the abdominal wall about 1 cm to the left of the spinal 
cord. The ovary was exteriorized and placed on a sterile drape. Silk sutures were used to ligate 
the oviduct and anterior connective tissue prior to excising the ovary. The body wall was then 
sutured with dissolvable sutures and wound clips were used to close the skin. The procedure 
was repeated on the animal’s right side. Wound clips are removed 4-5 days after surgery and 4 
weeks later the ovariectomized mice were used in experiments. 
Transthoracic echocardiography was performed on Admhi/hi and littermate wildtype mice 
under anesthesia (3% isoflurane) with a VisualSonics Vevo770 high-resolution imaging system. 
All studies were approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. 
Gene expression analysis 
Gene expression was analyzed by quantitative (q)RT-PCR with the Mx3000P Real-Time 
PCR System from Stratagene. Adm (RefSeq ID: NM_009627.1) gene expression was assessed 
using primers and a probe described previously (245). Taqman Gene Expression Assays for 
EIG121L (RefSeq ID: NM_172706.3, cat# 4351372), miR-879 (RefSeq ID: NR_030537.1, cat# 
4427975), Gapdh (RefSeq ID: NM_001289726.1, cat# 4308313) and snoRNA-202 (cat# 
4427975), were purchased from Applied Biosystems. Samples were assessed three times in 
triplicate. Relative levels of gene expression were determined using the ∆∆Ct method. 
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Plasmids, mutagenesis, transfection, and luciferase assay 
700-bp of the 3´UTR region of the mAdm gene (112 bp after Adm stop codon) was 
cloned into the Xba I site of pGL3-Promoter Vector (Promega, E1761). The QuikChange® II 
Site-Directed Mutagenesis Kit from Stratagene was used to introduce specific point mutations in 
the miR-25 and miR-879 binding sites. MicroRNA-25 (AM17100-PM10584), microRNA-879 
(AM17100-PM12276), and a scrambled negative control microRNA (AM4611) were ordered 
from Ambion. HEK293T cells were transfected with 10nM microRNAs, 250ng/ml plasmids, and 
5ng/ml Renilla luciferase (Rluc) reporter vectors using Lipofectamine 2000 (Invitrogen, 11668-
027) in accordance with the manufacturer’s protocol.  48h after transfection, the cells were lysed 
and luciferase activities were measured with the Dual-Glo luciferase assay system (Promega, 
E2920).  
Statistics 
Statistical analyses were performed with JMP software (SAS). One-way ANOVA was 
used to determine significance at p < 0.05. In all figures, error bars represent SEM. 
 
Results 
 
Dramatic, estrogen-dependent increase of Adm in female Admhi/hi heart 
 Previous studies have characterized the generation of the Adm over-expression model 
(126), referred to as Admhi/hi mice, as well as the developmental (245) and reproductive 
phenotypes (126) observed in this line. These mice were generated by the gene-targeted 
insertion of the stable bovine growth hormone (bGH) 3"UTR upstream of the unstable native 
Adm 3"UTR (126), thereby resulting in accumulation of Adm mRNA and increased expression. 
Through this approach, 5"UTR regulatory elements remain unchanged, thereby preventing 
disruption of the native regulatory elements of Adm. This approach, however, does disrupt the 
native 3"UTR regulatory elements with the insertion of the bGH 3"UTR. When the expression 
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levels of Adm in female tissues were compared to the levels previously reported in males (245), 
similar degrees of Adm over-expression in the adrenal gland, reproductive organs, intestine, 
skin, liver, brain, kidney and spleen were observed between the two sexes (Figure 1A). 
However, upon examination of Adm expression in the heart, a dramatic 60-fold increase in Adm 
was observed in Admhi/hi female hearts relative to wildtype littermates (Figure 1A). This 60-fold 
increase in expression was reduced to a 4-fold increase of expression with ovariectomy of 
female animals, which is comparable to the increase observed in male Admhi/hi mice (245). 
Previous studies by Watanabe et al. (240) using ovariectomized mice demonstrated that Adm is 
regulated by estrogen through ERα-dependent mechanisms; however, since these experiments 
were performed using estrogen infusion, it remains unclear whether endogenous changes in 
estrogen can promote detectable differences in Adm expression. This study revealed a 
dramatic, estrogen-dependent increase in Adm expression in Admhi/hi females suggesting that 
shifting levels of endogenous estrogen with the different phases of the estrus cycle are capable 
of regulating Adm expression. Therefore, an assessement of Adm expression levels from heart 
and uterus samples of wildtype 129S6/SvEv, abbreviated as SvEV, female mice in either 
diestrus or estrus, the low and high phases of the estrus cycle, respectively was conducted. 
This approach revealed a modest, but significant increase of Adm transcript levels in the hearts 
and uteri of estrus females compared to diestrus females (Figure 1B), indicating that changes 
in endogenous estrogen levels can modulate Adm expression in vivo.  
 
Enhanced contractility of Admhi/hi females is reversed with ovariectomy 
 Several studies have suggested that AM has inotropic properties in the heart (87, 217), 
prompting an investigation of any potential functional consequences resulting from this 60-fold 
increase in cardiac Adm. To do this, cardiac function was determined using echocardiography. 
As the results in Table 1 demonstrate, Admhi/hi females have enhanced heart function, as 
indicated by an increase in both the ejection fraction and fractional shortening, compared to 
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wildtype littermates, consistent with the published inotropic properties of AM. Additionally, 
ovariectomy of females prior to the onset of puberty reverted the heart function of Admhi/hi 
females to wildtype levels, indicating that the robust cardiac over-expression of Adm was 
responsible for the enhanced function. No significant differences were noted in the internal 
chamber dimensions, indicating that Admhi/hi females do not have dilated left ventricles. Finally, 
assessment of male cardiac function by echocardiography revealed no significant difference in 
ejection fraction between wildtype and Admhi/hi males (42.42±5.49 vs. 42.19±3.04), indicating 
that a three- to four-fold increase of cardiac AM is insufficient for altering cardiac function. 
 
Estrogen drives the expression of miR-879, which targets the Adm 3´UTR 
 Under basal conditions, Adm expression levels differ in a sex-dependent manner in the 
heart, highlighting the importance of estrogen-regulation of endogenous Adm. Compared to the 
expression of Adm in the hearts of wildtype males (data previously published in reference 
(245)), intact wildtype females express significantly more Adm. This sex-dependent difference in 
Adm expression in wildtype animals, however, is only about 5-fold; not the 50-fold difference 
observed between Admhi/hi males (reported in reference (245)) and intact Admhi/hi females. 
Consistent with notion that estrogen mediates Adm expression in an estrogen-dependent 
manner in the heart, ovariectomization of wildtype females results in Adm expression levels 
indistinguishable from wildtype males; while ovariectomization of Admhi/hi females results in a 4-
fold elevation of Adm expression over wildtype animals, which is comparable to the difference 
observed between male wildtype and Admhi/hi mice (245). Together, these data suggested that 
estrogen acts on both the 5"UTR and 3"UTR of Adm to provide fine-tuned control of Adm 
expression in response to hormonal cues. Therefore, the hypothesis was put forth that 
estrogen-induced microRNAs target Adm to decrease expression levels in the heart in the 
presence of estrogen and that by inserting the bGH 3´UTR upstream of the native Adm 3´UTR, 
this important regulatory process had been disrupted. In support of this hypothesis, several 
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groups have identified microRNAs that are indeed induced by estrogen (12, 26, 35, 172, 177), 
and so, the 3´UTR of Adm was examined for any predicted target sites of microRNAs that are 
up-regulated by estrogen. Of the 54 microRNAs that are predicted to target the mouse Adm 
3´UTR, 15 of these predicted target sites were for estrogen-induced microRNAs (Figure 2A). 
During this analysis, a target site for the poorly characterized microRNA, miR-879, was noticed 
in the Adm 3´UTR. This particular microRNA was of interest because it is located within a gene 
called estrogen-induced gene 121-like, abbreviated as Eig121l. Currently, very little is known 
about Eig121l and miR-879, so the regulation of Eig121l and miR-879 by estrogen was 
interrogated. Using RNA extracted from heart lysates of ovariectomized, diestrus, and estrus 
females, the relative expression of Eig121l and miR-879 were assessed by qRT-PCR. This 
experiment revealed that with increasing levels of endogenous estrogen, the expression of 
Eig121l (Figure 2B) and miR-879 (Figure 2C) increased significantly, indicating that Eig121l 
and the residing microRNA, miR-879, are regulated by estrogen.  
 
MicroRNA-879 destabilizes Adm through its predicted target site 
 Having confirmed that miR-879 is up-regulated by endogenous estrogen in the heart, the 
next objective was to determine whether this microRNA can indeed interact with the 3´UTR of 
Adm to reduce transcript levels. To accomplish this, the luciferase gene within the pGL3-
promoter vector was stabilized with 700 base pairs of the mouse Adm 3´UTR, labeled as 
Adm700;native (Figure 3A), thereby allowing for the use of the relative amount of luciferase 
luminescence as a read-out of Adm gene stability. To demonstrate that miR-879 works through 
the predicted target site in the Adm 3´UTR, two vectors were generated in which separate single 
point mutations were created within the predicted target site for miR-879, designated as 
Adm700;miR-879m1 and Adm700;miR-879m2 (Figure 3A). Additionally, a vector was created with 
a single point mutation in the predicted target site for miR-25, the positive control of Adm de-
stabilization for this experiment, represented as Adm700;miR25m1 (Figure 3A). The reason for 
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selecting this microRNA as a positive control was two-fold; first, miR-25 is the most highly 
conserved microRNA to target the Adm 3´UTR, and second, miR-25 is also regulated by 
estrogen (26), further supporting the hypothesis that estrogen-driven microRNAs help balance 
Adm expression in the female heart. As shown in Figure 3B, transfection with the 
Adm700;native vector and either miR-879 or miR-25 resulted in a significant reduction in the 
amount of luciferase luminescence normalized to the total amount of Renilla luminescence, 
indicating that both microRNAs can act on the Adm 3´UTR to destabilize expression. This 
approach also demonstrated that these microRNAs were acting specifically through the 
predicted target sites, since transfection of the mutated vectors along with the proper microRNA 
did not alter the relative luminescence (Figure 3B).    
 
Discussion 
 
 Based on the findings in this study, a balanced model of the regulation of Adm by 
estrogen is proposed (Figure 4). To summarize, previous studies have demonstrated that Adm 
expression is up-regulated by estrogen through ERα (240). This study indicates that under 
normal circumstances, estrogen drives the expression of a cohort of microRNAs, including miR-
879, that target the Adm 3´UTR, resulting in balanced Adm expression. In the case of the 
Admhi/hi mice, the introduction of the bGH 3´UTR most likely displaced the native target sites for 
these estrogen-induced microRNAs, rendering them ineffective in balancing the positive 
transcriptional force of estrogen from the 5"UTR of Adm, resulting in dramatic over-expression 
of Adm in the female heart. This study also found that this dramatic over-expression of Adm had 
physiological consequences, including enhanced contractility of the cardiomyocytes. Although 
this study cannot rule out the possibility that the modification of the Adm 3"UTR with the 
generation of the Admhi/hi line has altered the responsiveness of the promoter due to 
displacement of repressive cis-acting elements, the large number of estrogen-induced 
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microRNAs that target the Adm 3"UTR indicates an important role for estrogen-induced 
microRNAs in Adm gene regulation. Additionally, results from the luciferase assay revealed that 
modification of even one base pair within the predicted target site for the estrogen-induced 
microRNA miR-25 severely reduced Adm expression, indicating that this microRNA may play a 
critical role in the regulation of Adm, although this requires further study.  
The fine-tuned balance of gene expression levels by microRNAs has emerged as a 
powerful and pervasive mechanism for controlling numerous biological processes from early 
development to pathological disease progression (2, 205). Indeed, the coordinated expression 
of microRNAs in response to cellular and physiological stimuli can be exploited in order to 
control both positive and negative regulatory factors within a biological pathway or signaling 
cascade (148). Thus, microRNAs can provide a buffer against large and detrimental variations 
in gene expression in response to (patho)physiological stimuli, such as estrogen. This study has 
revealed the importance of this type of balanced gene regulation for a particular 
cardioprotective, estrogen-regulated gene, Adm, in the heart. Considering that it has been 
notoriously difficult to identify the downstream target genes of estrogen signaling that account 
for sex differences in cardiovascular disease susceptibility and progression (139), it seemed 
possible that similar microRNA regulatory mechanisms might be in place for other estrogen-
regulated target genes with important roles in cardiovascular disease. 
To test this theory, other targets of miR-879 were examined using the microRNA.org 
database, and it was immediately noted that the Kcnj2 gene, encoding the Kir2.1 potassium 
channel, was one of the top ten genes predicted to be down-regulated by miR-879. Kcnj2 is 
highly expressed in the heart (189) and contains species-conserved ERα binding sites within its 
promoter. Importantly, mutations in this gene are associated with Andersen syndrome (long QT 
syndrome type-7), of which a symptom is ventricular arrhythmia (226). Therefore, the cardiac 
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function of miR-879 is likely to extend to additional target genes with roles in cardiac 
conductance and cardiovascular disease, and this will be an exciting area for future study.  
It is noteworthy that numerous potassium and cardiac conductance ion channels are 
significantly down-regulated in female hearts compared to males at the basal state (61). 
However, the regulatory mechanisms contributing to these sex differences in gene expression 
have yet to be explained. Therefore, the 3´UTRs of the cardiac conductance ion channels 
identified by Gaborit et al. as reduced in female hearts compared to males (61) were examined 
for binding sites of microRNAs that are positively regulated by estrogen (26). This analysis also 
included KCNA5, a potassium channel differentially expressed with sex (17, 51), and KCND2, a 
potassium channel associated with long QT syndrome in mice (10). Interestingly, all of the ion 
channels analyzed contained four or more target sites, and half contained ten or more target 
sites, for microRNAs that are up-regulated by estrogen. The genes identified with a high 
proportion of target sites for estrogen-regulated microRNAs were ABCC4, KCNJ11, KCNE1, 
GJA1, KCNA5, and KCND2. Therefore, future studies to elucidate the molecular networks that 
underlie the sex-dependent differences in ion channel gene expression in the heart should 
include an assessment of estrogen-regulated microRNAs. 
Finally, considering that the inotropic properties of AM on cardiomyocytes has been 
controversial (87, 88, 211, 217), the comparison of the contractile function in intact and 
ovariectomized Admhi/hi female mice herein helps to clarify the effects of AM dosage on cardiac 
contractility. This study found that the modest, but physiologically relevant 4-fold increase of AM 
in ovariectomized Admhi/hi females did not alter cardiac function whereas, in intact Admhi/hi 
females, estrogen drives Adm expression to levels 60 times greater than wildtype counterparts, 
which in turn significantly enhances cardiac function. With regard to the period immediately 
following the onset of myocardial infarction, it is therefore possible that the robust, yet transient 
increases in AM, through the action of HIF-1 (64), may occur in order to help sustain cardiac 
function. But then, how persistently elevated plasma AM can ultimately be correlated to poor 
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patient survival remains curious. It also remains under-studied whether the clinically-diagnostic 
plasma levels of AM in cardiovascular disease differ between men and women. The results from 
this study highlight the importance of carefully considering hormonal status when evaluating AM 
during cardiovascular disease. Results from this work underscore the importance of carefully 
evaluating estrogen-regulated genes and pathways, including microRNAs, as underlying factors 
contributing to sex differences in cardiovascular disease susceptibility and progression. 
 
Perspectives and Significance 
 
 Hormonal signals, including estrogen, mediate gene expression changes that contribute 
to sex-dependent differences in physiological and pathological states. In this study, 
displacement of the native Adm 3"UTR in the generation of the Admhi/hi mouse line led to the 
serendipitous appreciation of the important role played by estrogen-induced microRNAs in the 
regulation of Adm. Additionally, this study alludes to the presence of tissue-specific regulatory 
networks of microRNAs, as the 60-fold elevation of Adm observed in Admhi/hi females was 
restricted to the heart. Given the elevation of plasma AM levels during human disease (97), and 
the cardioprotective properties of AM (20, 78, 170, 173, 203), future studies should examine the 
implications of this dramatic elevation of AM on cardiovascular pathology following an insult. 
Additionally, further work investigating the relative levels of estrogen-induced microRNAs across 
tissues should be conducted to enhance the understanding of the complex networks regulating 
Adm expression. Finally, further exploration into the role of estrogen-induced microRNAs in the 
regulation of cardiac ion channels should be investigated as a potential mechanism underlying 
sex-dependent differences in diseases involving cardiac contraction.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Adm expression is drastically up-regulated in the heart in an estrogen-
dependent manner.  
A. Quantitative RT-PCR (qRT-PCR) analysis for Adm from Adm+/+ and Admhi/hi intact females 
normalized to calibrator. Additionally, Adm expression was analyzed by qRT-PCR in the hearts 
of ovariectomized (OVX) Adm+/+ and Admhi/hi female mouse hearts and normalized to calibrator. 
B. qRT-PCR analysis of Adm levels from wildtype SvEV heart and uterus samples isolated 
during diestrus and estrus. All values represent means±SEM. *p<0.05, ***p<0.0001 
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Figure 4.2. Regulation of Adm by estrogen-regulated microRNAs.  
A. Schematic of the microRNA binding sites located in the M. musculus 3´UTR of Adm as 
identified by the MicroCosm Targets database (http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/). Lines indicate microRNA binding sites, while bold microRNA 
names indicate estrogen-regulated microRNAs. 1Castellano L et al. (2009); 2Chung TKH et al. 
(2009); 3Pan Q et al. (2007); 4Bhat-Nakshatri P et al. (2009); 5Nothnick WB et al. (2010). B. 
qRT-PCR analysis for Eig121l from ovariectomized (OVX), diestrus, and estrus C57Bl6/J female 
hearts normalized to mouse calibrator. C. qRT-PCR analysis of miR-879 expression from the 
hearts of ovariectomized (OVX), diestrus, and estrus C57Bl6/J females. Expression of miR-879 
was normalized to sno-202 and relative expression was calculated using the ∆∆CT method. All 
values are means±SEM. *p<0.05, **p<0.001, ***p<0.0001 
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Figure 4.3. Estrogen-regulated microRNA-879 negatively regulates Adm expression. 
A. Graphical representation of luciferase vectors used for assessing regulation of Adm by 
microRNAs. Adm700;native refers to the modified pGL3-promoter vector in which luciferase 
expression was stabilized by 700-bp of the mouse Adm 3´UTR. Two separate sets of point 
mutations were made to the predicted miR-879 target sites in the Adm700 construct and are 
designated as Adm700;miR-879m1 and Adm700;miR-879m2. Additionally, the target site for miR-
25 was mutated and is designated Adm700;miR-25m1. Asterisks indicate location of point 
mutations. B. Relative luminescence was calculated by normalizing luciferase luminescence to 
Renilla luminescence. Scram refers to the scrambled negative control. All values represent 
means±SEM. ***p<0.0001 
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Figure 4.4. Model of Adm regulation and physiology.  
ERα, estrogen receptor-α; Adm, adrenomedullin; Eig121l, estrogen-induced gene 121-like; miR-
879, microRNA-879.  
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CHAPTER V: ADRENOMEDULLIN OVER-EXPRESSION DOES NOT ALTER PATHOLOGY IN 
RENIN TRANSGENIC MODEL OF CHRONIC HYPERTENSION3 
 
Introduction 
 Cardiovascular disease continues to be a leading cause of mortality in developed 
countries despite improved efforts to educate the public about lifestyle changes that can 
minimize risk. Hypertension affects nearly a third of adults in the United States (66) and is a 
major risk factor for more severe cardiovascular complications in the future if not controlled. In 
addition to changes to exercise routines and restricting sodium intake, individuals with 
hypertension may be prescribed a number of pharmaceutical drugs in an attempt to rein in 
blood pressure levels, including: diuretics, beta-blockers, ACE inhibitors, vasodilators, and 
blockers for the AngII receptor. Many of the existing therapies target the renin-angiotensin 
aldosterone system (RAAS), since chronic over-activation of this system causes fluid retention, 
and thus hypertension. Although these drugs help control blood pressure for many individuals, 
for some, blood pressure remains elevated despite aggressive treatment with several different 
drugs, a condition termed drug-resistant hypertension (224). Therefore, there is a great need to 
develop additional therapeutics that target factors external to the RAAS to improve blood 
pressure control and reduce the risk of heart disease and stroke.  
 Adrenomedullin (Adm = gene; AM = protein) is a small, widely expressed peptide with 
many cardioprotective properties. Several studies performed both in vitro and in vivo have 
demonstrated that AM has vasodilatory (108), inotropic (87), anti-fibrotic (168), and anti-
hypertrophic (140, 231) functions. Together, these functions suggest a beneficial role for AM in 
the cardiovascular system, particularly during disease. In fact, several studies to date have
                                                       
3Contributing authors include: Sarah E. Wetzel-Strong and Kathleen M. Caron  
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indicated that AM is indeed a cardioprotective peptide (20, 203). Studies using Adm 
heterozygous mice have revealed a worsening of cardiovascular disease in a sex-specific 
manner compared to animals with wildtype levels of AM (20), indicating the importance of this 
peptide in modulating injury during disease. Additionally, several groups have infused AM into 
animals and humans during cardiovascular disease and have noted a beneficial effect on blood 
pressure and prognosis (98, 157-159, 166, 228). However, it remains unclear whether genetic 
up-regulation of AM alters cardiovascular disease progression. Finally, a limited number of 
studies have found associations between various Adm polymorphisms and hypertension risk 
(90, 112), indicating a potential direct role for AM in disease progression. 
 Until recently, accurately measuring circulating levels of AM in the blood has posed a 
significant challenge due to the affinity of AM for its binding partner, complement factor H (CFH) 
(184), as well as its short half life (146). To circumvent these problems, an assay has been 
developed to measure circulating levels of mid-regional pro-AM (MR-proAM) (155). This stable 
peptide fragment is produced in equal proportions to AM during the cleavage process that 
occurs to produce mature AM (155), and therefore is a reliable read-out of AM circulating in the 
plasma. Measurement of MR-proAM during many human disease conditions have revealed that 
in many instances, including during cardiovascular disease, plasma levels of AM are elevated 
above baseline levels (97). Recently, clinicians have been exploring the usefulness of plasma 
MR-proAM levels as a biomarker for disease severity (31, 48, 101, 111, 142). With regards to 
cardiovascular disease, several studies have indicated that MR-proAM levels are a useful 
biomarker of cardiovascular disease severity (48, 142). In fact, these studies have revealed that 
MR-proAM may be a better biomarker than traditional cardiovascular biomarkers, such as BNP, 
by allowing for better stratification of patient risk and prediction of mortality following patient 
discharge (142). These findings clearly highlight the clinical significance of AM during human 
disease; supporting previous work performed using animal models. 
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 Given the clear importance of AM as a protective peptide during cardiovascular disease, 
we were interested in determining whether genetic over-expression of Adm at levels 
comparable to the elevation observed in human patients with cardiovascular disease offered 
any further protection. To address this question, we crossed the Adm over-expression line 
(Admhi/hi), which has a three-fold elevation in circulating levels of AM in the plasma and a three- 
to 15-fold elevation in Adm gene expression within tissues compared to wildtype controls (245), 
to the renin transgenic mouse line, abbreviated as RenTgMK. The RenTgMK line is a well-
characterized model of chronic hypertension (21-23), in which a modified version of the renin 
gene is constitutively expressed from the liver, resulting in persistent activation of the renin-
angiotensin aldosterone system (RAAS). We then performed cardiovascular phenotyping on 
male RenTgMK:Adm+/+ and RenTgMK:Admhi/hi mice to assess differences in cardiomyocyte 
hypertrophy, cardiac function, and cardiac fibrosis.  
 
Methods 
Animals 
 Admhi/hi animals, maintained on a C57Bl6/J background, used for these studies were 
generated as previously described (126, 245) and crossed to the established RenTgMK line, 
maintained on a 129S6/SvEv (21). Genotyping was performed by PCR using previously 
described primers (23, 126). For these studies, male mice were maintained on a mixed 
C57Bl6/J x 129S6/SvEv background and studied at 2-, 3-, 6-, and 8-months of age. Control 
animals utilized in this study were wildtype and Admhi/hi age-matched animals maintained on a 
mixed C57Bl6/J x 129S6/SvEv background. Conscious echocardiograms were performed at 6- 
and 8-month of age by the Rodent Advanced Surgical Models Core lab at the University of 
North Carolina. Echocardiogram data was analyzed using Vevo2.2 software. All experiments 
were approved by the Institutional Animal Care and Use Committee of the University of North 
Carolina at Chapel Hill. 
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Gene expression analysis 
 Left ventricular tissue was collected and stored at -80°C in RNAlater (Ambion, AM7021) 
prior to RNA extraction. RNA was isolated from the ventricle tissue by a TriZol-chloroform 
extraction. Subsequently, the RNA was treated with DNaseI to degrade contaminating genomic 
DNA (Promega, M6101) prior to reverse transcription by M-MLV as described in the 
manufacturer’s protocol (Invitrogen, 28025-013). Gene expression was then assessed by 
quantitative reverse transcription (qRT)-PCR with the StepOne Plus Real-Time PCR system by 
Life Technologies. Primer and probe sequences for Calcrl, Ramp1, Ramp2, and Ramp3, have 
been previously described (41, 42, 127). Pre-designed primer/probe assay-on-demand sets 
from Applied Biosystems were used to assess Nppa (Applied Biosystems, Mm01255747_g1) 
and Col1a1 (Applied Biosystems, Mm00801666_g1) expression. Primer and probe sets for 
Gapdh (Applied Biosystems, 430813), Mouse eukaryotic translation elongation factor 1 alpha 1 
(Meef) (8), B2m (Applied Biosystems, Mm00437762_m1), and Polr2a (Applied Biosystems, 
Mm00839493_m1) were used for internal housekeeping controls. Relative levels of gene 
expression were determined by the ∆∆Ct method.  
Organ weight ratios 
 Prior to dissection, the animal was weighed and the body weight was recorded. The total 
weight of both kidneys was measured after dissection to obtain kidney weight. The chambers of 
the heart were dissected apart so that the left ventricle remained intact and individual chamber 
weights were recorded. The total heart weight was obtained by adding together the individual 
chamber weights. Tibias were also dissected and the length was measured using calipers. 
Kidney, heart, and chamber weights were normalized to body weight as well as tibia length to 
generate organ ratios. 
Histology 
 The left ventricle was cut in half along its axis and the right half (when the septum was 
facing up), was fixed in 4% paraformaldehyde overnight. After fixation, samples were embedded 
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in paraffin and 5µm sections were cut. Staining for hematoxylin and eosin (H&E) as well as 
Picrosirius red were performed following established protocols.  
Cardiomyocyte cross-sectional area analysis 
 Left ventricle sections stained with H&E were used to assess cardiomyocyte cross-
sectional area. For each animal, three distinct areas in the outer free wall of the ventricle, in 
which the cardiomyocytes were primarily oriented in a cross-sectional fashion, were randomly 
selected and imaged at 25x magnification. Using ImageJ software, the area of five cross-
sectional cardiomyocytes was measured per field to generate the average cardiomyocyte cross-
sectional area.  
Quantitation of perivascular and interstitial fibrosis 
 Perivascular and interstitial fibrosis were quantitated from left ventricle sections stained 
with Picrosirius Red. To assess perivascular fibrosis, images of three coronary vessels in cross-
section were obtained for each animal at 25x magnification. Then, using ImageJ software, the 
total thickening area, which includes the area of the fibrosis, intima layer, and lumen, was 
determined. Additionally, the intima and lumen area was measured to allow for determination of 
the fibrotic and intima areas individually through calculations. Finally, the lumen area was 
measured to account for vessel size. To determine the degree of interstitial fibrosis, images of 
the interstitial fibrosis near the apex of the left ventricle were obtained at 10x magnification. 
Using ImageJ software, a threshold analysis was performed to calculate the percent area of 
fibrosis. Briefly, the channels of the image were split. The area of fibrosis was determined by 
performing a threshold analysis of the green channel, as the Picrosirius red staining is most 
pronounced in this channel. Next, the total area of tissue present in the image was determined 
by performing a threshold analysis of the tissue visible in the blue channel and the percent area 
of collagen was calculated.  
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Statistical analysis 
 Statistical significance was determined by performing a two-tailed student’s t-test using 
GraphPad Prism software. Values of p<0.05 were considered significant. All values shown on 
graphs in figures represent the means±SEM.    
 
Results 
Over-expression of Adm does not alter left ventricle hypertrophy 
 We began assessing cardiomyocyte hypertrophy by determining heart weight to body 
weight (HW:BW) and left ventricle to body weight (LV:BW) ratios because hypertrophy 
increases the overall mass of the left ventricle. However, since Admhi/hi animals have increased 
HW:BW and LV:BW ratios at baseline due to cardiac hyperplasia during embryonic 
development (245), we represented these ratios as the percent change for the RenTgMK 
groups over the appropriate RenTgMK-negative controls. As expected, the hearts of both 
RenTgMK groups were visibly enlarged compared to non-RenTgMK controls. Notably, the 
hearts of RenTgMK:Admhi/hi animals were extremely enlarged due to the combination of 
baseline cardiac hyperplasia in the Admhi/hi line(reported in (245) and cardiomyocyte 
hypertrophy due to sustained activation of the RAAS. However, with this analysis, we found that 
there was no difference in the percent increase for either the HW:BW (Figure 1A) or LV:BW 
(Figure 1B) ratios between RenTgMK:Adm+/+ and RenTgMK:Admhi/hi animals. Together, these 
results indicate that hypertrophy is occurring at the same rate between RenTgMK:Adm+/+ and 
RenTgMK:Admhi/hi animals. Additionally, we recorded the weights of the kidneys, lung, and liver. 
When these organ weights were normalized to body weight, we found that RenTgMK:Admhi/hi 
mice had significantly larger kidneys at 8 months of age (Figure 1C); however, lung (Figure 1D) 
and liver (Figure 1E) weights did not differ with genotype.  
 To further confirm that cardiomyocyte hypertrophy is similar between RenTgMK:Adm+/+ 
and RenTgMK:Admhi/hi mice, we measured the cross-sectional area of cardiomyocytes from 
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H&E stained sections of the left ventricle (Figure 2A). This analysis revealed that the 
cardiomyocyte cross-sectional areas of RenTgMK:Adm+/+ and RenTgMK:Admhi/hi mice were 
elevated compared to non-RenTgMK controls (Figure 2B), although not significantly. Finally, we 
assessed the gene expression levels of Nppa in left ventricular tissue, as elevated Nppa levels 
are indicative of hypertrophy. From this analysis, we found that RenTgMK:Adm+/+ and 
RenTgMK:Admhi/hi mice had elevated expression of Nppa compared to the corresponding 
animals negative for the renin transgene (Figure 2C, D, and E), however, there was no 
appreciable difference between the two RenTgMK groups. These data indicate that although the 
hearts of RenTgMK mice are hypertrophied, over-expression of Adm does not ameliorate this 
hypertrophy.  
 
Perivascular and interstitial cardiac fibrosis are unchanged with Adm over-expression 
 In response to chronic pressure overload, fibrotic changes occur in the heart to provide 
structural support to the vessels and myocardium. Previous studies have found that AM can 
have anti-fibrotic effects (168), leading us to ask whether Adm over-expression attenuates the 
perivascular and interstitial fibrosis that occur in the RenTgMK model of chronic hypertension. 
To begin, we assessed the degree of perivascular fibrosis using left ventricle sections stained 
with Picorsirius Red (Figure 3A). As shown in Figure 5B, we measured the total area of vessel 
thickening, the intima layer area, and the area of the lumen. Using these measurements, we 
calculated the total thickening (Figure 3C), as well as the fibrotic (Figure 3D) and intima 
(Figure 3E) areas relative to the lumen size. Although these analyses did not reveal a 
difference in the degree of perivascular fibrosis between RenTgMK:Adm+/+ and 
RenTgMK:Admhi/hi mice (Figure 3C, D, and E), these results are confounded by the fact that 
animals positive for the renin transgene did not exhibit enhanced perivascular fibrosis compared 
to animals lacking the transgene.  
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 In addition to assessing changes in perivascular fibrosis, we also used sections stained 
with Picrosirius red to determine whether differences exist in the degree of interstitial fibrosis 
(Figure 4A). Using a threshold analysis to determine the percent area of fibrosis for a given 
area of tissue, we found that the degree of interstitial fibrosis did not differ between 
RenTgMK:Adm+/+ and RenTgMK:Admhi/hi male mice (Figure 4B). Similar to what was observed 
for the perivascular fibrosis, the RenTgMK animals did not display increased fibrosis compared 
to non-renin transgene controls, even in advanced stages of the disease in contrast to what has 
been previously reported for this model, making it impossible to draw an accurate conclusion 
from these results. Finally, we assessed gene expression levels of Col1a1 as a measure of 
collagen production, and thus a read out of fibrosis. From this analysis, we found that the 
relative expression of Col1a1 was not significantly different for any group analyzed at 2 months 
(Figure 4C), 3 months (Figure 4D), 6 months (Figure 4E), and 8 months (Figure 4F), reflecting 
the Picrosirius red findings.  
 
Over-expression of Adm does not alter cardiac function in renin transgene model 
 Finally, we assessed the impact of Adm over-expression on cardiac function in the 
RenTgMK model of chronic hypertension by performing echocardiography. As shown in Table 
1, we did not detect any significant differences in cardiac function between RenTgMK:Adm+/+ 
and RenTgMK:Admhi/hi males, although by 8-months of age, we observed a trend for reduced 
heart function in RenTgMK:Admhi/hi mice. This trend for decreased cardiac function can be 
attributed to a non-significant trend in dilation of the left ventricles of RenTgMK:Admhi/hi mice at 
8-months of age. Consistent with our data indicating no difference in the degree of left 
ventricular hypertrophy, we found no significant difference in wall thickness between 
RenTgMK:Adm+/+ and RenTgMK:Admhi/hi animals, although both groups had wall thicknesses 
that were significantly greater than age-matched non-RenTgMK+ controls. Together, these 
results indicate that Adm over-expression does not alter heart function in chronic hypertension, 
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and lends further support to the conclusion that hypertrophy is not altered by Adm over-
expression in this model.  
 
Discussion 
 In this study, we sought to determine the impact of constitutive three-fold elevation of AM 
in the context of chronic hypertension through the use of genetic mouse models. We found that 
AM over-expression did not alter the progression of cardiomyocyte hypertrophy in the renin 
transgenic model of chronic hypertension. Additionally, AM over-expression also did not alter 
the degree of fibrosis with disease progression. However, it is important to note that 
perivascular and interstitial fibrosis did not increase with advancing disease in the RenTgMK: 
Adm+/+ animals as previously described by Caron et al (21). Finally, AM over-expression did not 
significantly alter cardiac function, although we did observe a trend for reduced heart function in 
RenTgMK: Admhi/hi animals compared to RenTgMK: Adm+/+ controls. Although these results 
seem to indicate that AM over-expression does not confer additional cardioprotection during 
chronic hypertension, the altered disease progression observed in RenTgMK: Adm+/+ animals 
underscores the need to interpret the findings of this study cautiously. 
 Initial studies characterizing the RenTgMK line describe a progressive worsening of 
cardiac and kidney dysfunction with advancing age (20, 21, 23). Specifically, the degree of 
interstitial and perivascular fibrosis observed in the hearts of RenTgMK: Adm+/+ mice increases 
progressively, with significant fibrotic plaques observed in the left ventricle wall by six- to eight-
months of age (23). In this study, both RenTgMK: Adm+/+ and RenTgMK: Admhi/hi animals at six- 
and eight-months of age failed to display any noticeable increase in left ventricular fibrosis 
compared to non-RenTgMK-positive groups. There are several possibilities that could explain 
this lack of disease progression. For instance, it is possible that we acquired the incorrect 
RenTg line, and were therefore characterizing either the RenTgKC or RenTgARE lines. Studies 
by Caron et al (23) demonstrated that the RenTgKC and, in particular, the RenTgARE lines 
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present with a milder degree of hypertension, and thus, present with milder cardiac and kidney 
pathologies. Therefore, PCR primers were designed to allow for detection of either the MK 
sequence, which is present only in the RenTgMK line, or the ARE sequence, present only in the 
RenTgARE line, in order to determine the RenTg line utilized in the lab. From this approach, it 
was determined that the RenTg line used in these studies was, in fact, the RenTgMK line, 
therefore ruling out the possibility that we had inadvertently conducted these experiments in a 
less severe model of hypertension. Additionally, it is possible that the mixed genetic background 
utilized in this study has introduced a genetic modifier that has altered fibrosis progression. 
Other groups have demonstrated genetic background can alter the extent of fibrosis, 
cardiomyocyte hypertrophy, and inflammation in response to pressure overload on the heart (9). 
Therefore, it is likely that we inadvertently changed the genetic factors responsible for promoting 
cardiac fibrosis in the RenTgMK line by introducing the C57Bl6/J strain into this cross.  
 Previous studies have found that in the context of chronic hypertension, cardiomyocyte 
hypertrophy is exacerbated with a 50% reduction in AM (20), indicating that AM is an anti-
hypertrophic peptide. Therefore, we might have expected to observe a reduction in 
cardiomyocyte area with AM over-expression. One potential explanation for the lack of 
difference in cardiomyocyte hypertrophy between RenTgMK: Adm+/+ and RenTgMK: Admhi/hi 
mice is that wildtype levels of AM are necessary to protect against exacerbated hypertrophy, but 
additional AM is unable to overcome the hypertrophic response to pressure overload. Some 
studies have identified AM as a vasodilatory peptide (108), and therefore it might be expected 
that AM over-expression could suppress cardiac hypertrophy by reducing blood pressure. 
However, previous work with the Admhi/hi mice reveals that blood pressure is unchanged in this 
model of AM over-expression (245). Given that we did not observe a difference in cardiac 
hypertrophy, it is unlikely that blood pressure differences exist between RenTgMK: Adm+/+ and 
RenTgMK: Admhi/hi mice.  
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 The observed trend for reduced cardiac function in the RenTgMK: Admhi/hi mice is 
curious since in vitro and in vivo studies have generally suggested that AM exhibits inotropic 
properties (87, 216, 217). One possibility is that the hyperplastic hearts of the Admhi/hi line (245) 
exhibit a decline in function with advancing age, independent of any overlaying cardiovascular 
disease. Although cardiac hyperplasia has been described in several mouse models (27, 81, 
100, 183, 188, 227), the majority of these lines die due to a myriad of additional cardiac defects. 
However, Chaudhry et al (27) found that over-expression of cyclin A2 resulted in viable mice 
with hyperplastic hearts. Interestingly, at eight-months of age, the transgenic mice had a small, 
but significant decrease in cardiac function compared to wildtype controls (27), indicating that a 
similar phenomenon may occur in the Admhi/hi mice. In support of this theory, male Admhi/hi mice 
on a mixed 129S6/SvEv x C57Bl6/J background show a mild reduction in cardiac function 
compared to wildtype littermate controls at eight-months of age (Table 1); however this trend 
was not as pronounced as the trend observed between RenTgMK: Adm+/+ and RenTgMK: 
Admhi/hi mice. Thus, further longer-term studies are required to determine the underlying cause 
of the observed functional differences in aging Admhi/hi animals. 
 Although the data presented here seem to indicate that AM over-expression does not 
alter disease progression in the context of chronic hypertension, additional studies need to be 
conducted to definitively define the effect of AM over-expression during this disease. One way 
to address this question is through the infusion of AngII via osmotic minipumps into wildtype and 
Admhi/hi animals. Through this approach, hypertension can be achieved without introducing the 
confounding variable of a mixed genetic background. Additionally, this approach allows animals 
to develop normally before the onset of hypertension in adulthood, thereby more closely 
mimicking the human condition. Another potential approach that could be utilized is a renal 
artery clip model (70). This approach promotes an increase in AngII production by the kidney, 
ultimately leading to hypertension. Since this is a surgical model of hypertension, mixed genetic 
backgrounds can be avoided. However, as with any surgical model, the variability between 
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animals is greater due to slight differences in the surgical procedure on each animal, such as 
clip placement in this instance. Therefore, large numbers of animals would be required to 
accurately detect any differences attributed to genotype. Finally, to address the effect of 
pressure overload specifically on the heart, transaortic constriction could be performed. 
Although this approach is not a model of hypertension, and therefore cannot be used to draw 
conclusions regarding the role of elevated AM during human hypertension, this approach does 
allow for an assessment of the influence of AM over-expression on cardiac changes following 
an increase in load on the left ventricle. This approach could provide conclusive insight 
regarding the effect of AM over-expression on cardiomyocyte hypertrophy, as well as the impact 
on cardiac fibrosis.  
 In conclusion, this study attempted to decipher the effect of AM over-expression on 
disease progression in chronic hypertension. Presumably due to the mixed genetic background 
of the animals used for these experiments, disease pathologies did not progress as anticipated 
in RenTgMK: Adm+/+ control animals, thereby making it difficult to draw conclusions from these 
findings. However, it seems likely that AM over-expression may have a minimal impact on 
cardiomyocyte hypertrophy, although this finding needs verification. Additionally, it appears that 
AM over-expression promotes a reduction in cardiac function, especially with advancing age. 
However, the explanation for this observation remains elusive and warrants closer study. 
Together, the results from this study indicate that over-expression of AM during hypertension 
may, at best, be minimally beneficial.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Heart and organ ratios of RenTgMK;Adm+/+ and RenTgMK;Admhi/hi males over 
time. 
A. Heart weight to body weight ratios (HW:BW) represented as a percent change compared to 
corresponding non-RenTgMK+ controls. B. Left ventricle to body weight ratios (LV:BW) 
represented as the percent change compared to appropriate non-RenTgMK+ controls. C. 
Kidney weight to body weight ratios. D. Lung weight to body weight ratios. E. Liver weight to 
body weight ratios. 
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Figure 5.2. Over-expression of Adm does not alter the degree of cardiomyocyte 
hypertrophy.  
A. Representative images of H&E stained sections of the left ventricle used for measuring 
cardiomyocyte cross-sectional area. All images obtained at 40x magnification. B. The 
cardiomyocyte (CM) cross-sectional area was determined by measuring the area of 15 
cardiomyocytes per animal from H&E stained sections (n = 3-6). C. Quantitative RT-PCR (qRT-
PCR) was performed using RNA isolated from the left ventricle of 2-month old animals. Relative 
expression of Nppa was determined by normalizing to the housekeeping gene B2m using the 
∆∆CT method. D. Relative expression of Nppa from left ventricle samples of 3-month old 
animals. E. Relative expression of Nppa from left ventricle samples of 6-month old animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Perivascular fibrosis does not differ with Adm over-expression. 
A. Representative images of coronary vessels stained with Picrosirius Red. All images obtained 
at 25x magnification. B. Schematic demonstrating areas measured for quantitation. C. The 
normalized total thickening was determined by subtracting the total thickening (line a shown in 
panel B) from the lumen area (line c in panel B) and dividing by the lumen size (line c in panel 
B). Three vessels were measured from each animal for this analysis (n = 3-7). D. The 
normalized fibrotic area was determined by subtracting the measured total thickening area (line 
a in panel B) from the measured intima area (line b in panel B) and dividing by the lumen area 
(line c in panel B). For this analysis, three vessels were measured from each animal (n = 3-7). 
E. The normalized intima thickening was determined by subtracting the intima area 
measurement (line b in panel B) from the lumen area (line c in panel B) and dividing by the 
lumen area (line c in panel B). Three vessels were measured from each animal (n = 3-7).  
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Figure 5.4. Adm over-expression does not alter the degree of interstitial fibrosis within 
the left ventricle.  
A. Representative images of interstitial fibrosis at the apex of the left ventricle visualized with 
Picrosirius Red staining. All images obtained at 10x magnification. The collagen area fraction 
was determined by performing a threshold analysis using ImageJ software using 10x images of 
fibrosis at the apex of the left ventricle. B. Relative expression of Col1a1 in the left ventricle of 2-
month old males was determined by qRT-PCR. C. Relative expression levels of Col1a1 from left 
ventricle samples of 3-month old males. D. Relative expression of Col1a1 in the left ventricle 
from 6-month old males. E. Relative expression of Col1a1 in the left ventricle of 8-month old 
males.  
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CHAPTER VI: CONCLUSIONS AND FUTURE DIRECTIONS 
Summary
 In summary, the results and conclusions from these studies further elucidate the role of 
AM in cardiac development. Specifically, the role of epicardial-derived AM in cardiac 
development has been demonstrated, opening many interesting avenues of future study. 
Additionally, these studies have highlighted the importance of estrogen-induced microRNAs in 
the balance of Adm expression in the female heart, and potentially reveal one mechanism 
underlying sex-dependent differences in cardiovascular health. Finally, studies presented in this 
dissertation have begun to assess the effect of physiologically elevated AM levels on 
cardiovascular health during chronic hypertension; although further studies in this area need to 
be conducted to definitively assess the impact of AM in this context to remove the confounding 
effect of mouse strain.   
 
Current State of the Cardiovascular Field 
Epicardium during cardiac development and regeneration 
 Although much advancement has been made in delineating the function of the 
epicardium during cardiac development, further studies into the signaling mechanisms 
regulating these processes are needed. One recent study in zebrafish has demonstrated that a 
heartbeat is essential for proper epicardium formation (185). Specifically, this study found that in 
zebrafish, a heartbeat is required for migration of epicardial cells to the heart from the PEO and 
for expansion of the epicardium over the heart surface after the initial seeding of epicardial cells 
(185). Further studies investigating the signaling pathways that are activated by the contracting 
myocardium to regulate migration are warranted.  
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Several studies have demonstrated that the epicardium plays an important role in the 
development of the conduction system (255) and the cardiac valves (244). Although the 
epicardium does not appear to directly contribute to the formation of the atrioventricular (AV) 
conduction axis (1), studies have demonstrated that EPDCs contribute to the formation of the 
annulus fibrosus (244, 255). The annulus fibrosus is responsible for insulating the ventricular 
walls from the electrical impulses fired in the atria to prevent premature contraction of the 
ventricles. Therefore, studies further investigating the relationship between epicardium 
formation, conduction diseases and arrhythmias may prove fruitful. In addition, lineage-tracing 
studies have determined that EPDCs replace the endocardial-derived fibroblasts in the AV 
lateral cushions (244). Further studies into the signaling mechanisms regulating this process 
and the potential implications in adulthood are still needed.  
 Unlike mammals, the heart of adult zebrafish can regenerate after injury (71, 186), and 
the epicardium has been implicated in the repair process (85, 103, 238, 251). Since scar 
formation negatively impacts long-term prognosis after injury, there has been a recent surge of 
interest in clarifying the mechanisms underlying this regenerative potential and translating these 
findings into mammals. Recently, Zhao et al (251) have determined that Notch signaling 
activation in the epicardium and endocardium is essential for cardiomyocyte proliferation in the 
compact zone. Specifically, this study determined that loss of Notch signaling resulted in scar 
formation, rather than regeneration, reflecting the wound healing process that occurs in other 
vertebrates (251). Interestingly, this study found that the epicardium still becomes activated with 
the loss of Notch signaling and that coronary regeneration is unaffected, indicating that 
regeneration is not prevented in this context by inadequate vascularization in the injured zone 
(251). However, this study revealed that cardiomyocyte proliferation is extremely sensitive to the 
amount of Notch signaling as over-activation of the Notch pathway also impaired regeneration 
(251). Several studies have suggested a link between AM and the Notch signaling pathway in 
the vasculature (118, 134, 162, 250); however, it remains unclear whether AM is up- or 
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downstream of Notch. Therefore, further studies investigating the mechanisms regulating Notch 
signaling in the epicardium and the potential role of AM in this process are warranted.  
Other studies have indicated that ECM deposition by the epicardium is critical for zebrafish 
cardiac regeneration (238). Additionally, this study found that injury induced the expression of a 
fibronectin receptor in cardiomyocytes, highlighting the importance of fibronectin deposition for 
proper repopulation of the injured site by cardiomyocytes (238). Further studies regarding the 
mechanisms underlying the role of ECM in cardiomyocyte proliferation and the removal of ECM 
after regeneration may be valuable. Finally, Huang et al found that IGF signaling plays an 
important role in the regenerative process of zebrafish hearts (85), in addition to the previously 
described role during normal cardiac development (128). Therefore, it will be interesting to 
determine if other epicardial-derived growth factors involved in normal cardiac development can 
also contribute to cardiac regeneration.  
 
Role of the epicardium during cardiovascular disease 
 Although advancements in modern medicine have enhanced survival following 
myocardial infarction, scar formation in the heart remains an unsolved problem, ultimately 
leading to complications later in life. Unsurprisingly, there has been a surge in interest to heal 
the scarred tissue either through repopulation of the injured area with stem cells or by other 
regenerative mechanisms. Since some studies have suggested that the epicardium may be a 
source of cardiac stem cells (131) and zebrafish studies have demonstrated a critical role for the 
epicardium in cardiac regeneration (85, 103, 238, 251), several groups have focused on 
determining the potential of the epicardium for repair following injury.  
 Recent work by Bollini et al (15) has investigated whether activated epicardial cells are 
similar to EPDCs generated during embryonic development. This study found that adult EPDCs 
exhibit a great degree of diversity (15). For instance, some of these EPDCs express markers of 
cardiac progenitor cells, while others appear to be programmed for a mesenchymal lineage 
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(15). This study also found that the surface markers of embryonic EPDCs differ from adult 
EPDCs in several ways (15), including increased expression of several stem cell and 
mesenchymal cell markers, such as Sca-1, CD45, CD44, and CD90. This indicates that distinct 
signaling mechanisms may be involved in the derivation of EPDCs at different stages of life and 
following injury. These findings underscore the challenges faced by researchers attempting to 
regenerate the adult heart from the activated epicardium and highlight the need to identify the 
signaling mechanisms determining EPDC fate.  
 A limited number of studies have sought to identify activators of epicardial genes 
following epicardial reactivation after an injury. One recent study by Huang et al (84) has 
identified an important role for C/EBP transcription factors in the regulation of Raldh2 and Wt1 
expression during embryonic development and adult disease. Interestingly, this study found that 
suppression of C/EBP action resulted in improved heart function following myocardial infarction 
(84). This study also found a significant reduction in fibrosis and inflammation with the inhibition 
of C/EBP in the epicardium, which may contribute to the improved heart function (84). Further 
work uncovering the underlying mechanisms by which C/EBP suppression protects the heart 
would be interesting and could potentially uncover useful therapeutic targets. 
 
Sex-dependent differences in cardiovascular health 
 Recent studies have sought to advance the understanding of the mechanisms 
underlying sex-dependent differences in cardiovascular disease. These studies are of utmost 
importance in order to elucidate the reasons behind the unpredictability of hormone replacement 
therapy (HRT) in menopausal women. Recent clinical trials have indicated that inhibition of 
PDE5 may offer protection in various cardiovascular diseases (57, 197, 218). However, recent 
work by Sasaki et al (200) has revealed that estrogen is essential for the therapeutic 
effectiveness of PDE5-mediated compounds in females. This finding highlights the complicated 
nature of treating cardiovascular disease in women, especially after the onset of menopause. 
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Interestingly, this study also found that while estrogen enhanced the effectiveness of the PDE5 
inhibitor, sildenafil, in male mice, estrogen was not required in males to achieve therapeutic 
benefit (200), highlighting the differences that exist between the sexes in terms of hormone 
signaling.  
 Recently, investigators have also become interested in determining the role of hormones 
in male cardiac health. One recent study by Le et al (121) sought to determine the impact 
testosterone and estrogen in both sexes following myocardial infarction. Overall, hormones 
were detrimental to male cardiac health, primarily due to increased apoptosis (121). 
Interestingly, estrogen administration to males exacerbated infarct size, despite the fact that 
ERα and ERβ are expressed at similar levels in male and female hearts (121). This study, 
however, did not assess levels of GPR30, a membrane-bound GPCR that is capable of binding 
estrogen and promoting downstream signaling (6), which may account for the differing effect of 
estrogen between males and females. In summary, this study provides some insight regarding 
the role of hormones in damage following myocardial infarction between the sexes; however, 
further studies are required to fully elucidate the complex pathways involved in these processes.  
 Finally, the roles of several other pathways in mediating cardioprotection in females 
have been explored. For example, the suppression of reactive oxygen species (ROS) 
generation by estrogen has been suggested to be one mechanism by which female hearts are 
protected from damage in the context of ischemia-reperfusion injury (104). Recent work by Liu 
et al (133) has further elucidated the mechanisms underlying estrogen-mediated suppression of 
ROS generation. Specifically, this study found that estrogen increased the movement of 
phosphorylated p38β mitogen-activated protein kinase (p38β MAPK) into the mitochondria 
(133). Once in the mitochondria, p38β MAPK interacts with MnSOD, a member of the 
superoxide dismutase family, to activate it and thereby decrease ROS formation (133). Other 
studies have demonstrated that AM, which can be induced by estrogen (240), can offer 
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cardioprotection from ischemia-reperfusion injury by reducing ROS formation (105). Together, 
these, and many other studies, highlight the importance of estrogen in the reduction of ROS 
generation, which ultimately contributes to protection of the female heart upon re-oxygenation of 
the cardiac tissue. From these studies, it may be possible to generate therapeutics to reduce 
ROS generation in males and menopausal females following ischemia-reperfusion to mitigate 
cardiac damage.  
 
Future Directions 
Experiments related to AM signaling during cardiac development 
 One possible area of future study involves further exploration into the role of AM during 
cardiac development. Previous work by the Caron lab found that loss of CLR from endothelial 
cells through the use of Tie2-Cre mice(59) resulted in embryonic demise during mid-gestation 
with a phenotype similar to mice globally lacking CLR (42). Although this study clearly 
demonstrates the importance of endothelial AM signaling for proper lymphatic development, it 
remains unclear whether AM signaling on the epicardium, endocardium, or endothelial cells of 
the heart contribute to the observed cardiac defects as Tie2, the promoter driving Cre in the 
previously described study, is expressed in all of these cell populations (239).  
In order to address this question, the Calcrlfl/fl line could be crossed to the 
Wt1tm1(EGFP/cre)Wtp/J line, abbreviated as Wt1-Cre, to remove CLR specifically from the 
proepicardium and epicardium. Once this cross has been established, the first thing to 
determine is whether epicardial-specific loss of CLR is compatible with life. Therefore, several 
litters of animals can be generated to assess the number of Wt1-Cre: Calcrlfl/fl animals that 
survive to birth and beyond. Next, timed matings should be performed to assess cardiac 
morphology throughout development, regardless of whether Wt1-Cre: Calcrlfl/fl animals are 
viable. If it is found that these animals are not surviving to birth, the timed matings can also be 
used to determine at what developmental stage the embryos are dying. This genetic cross will 
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allow for the determination of the role of AM signaling on the epicardium during development, 
and might also permit an evaluation of the relative contribution of the lymphatic and 
cardiovascular abnormalities to embryonic demise.  
 In addition to examining the contribution of AM signaling on the epicardium to cardiac 
development, future studies can be conducted to determine whether AM over-expression alters 
the expression of growth factors or their respective receptors either in the epicardium or the 
myocardium to contribute to the cardiac hyperplasia observed in the Admhi/hi line. To begin, 
RNA-seq could be performed on embryonic cardiomyocyte and epicardial cell samples from 
wildtype and Admhi/hi animals to assess whether AM over-expression changes the expression 
levels of any growth factors or receptors. This approach will allow for the identification of 
interesting pathways in a rapid fashion and minimize the chance of overlooking important 
contributors to cardiac hyperplasia in this model. If this approach identifies growth factor 
pathways that are altered with AM over-expression, these gene expression changes can be 
individually verified by qRT-PCR. Upon confirming changes in gene expression, the role of 
these pathways in AM-driven cardiac hyperplasia can be determined through inhibition or 
activation of these pathways in vitro and in vivo.  
 In the event that AM over-expression is found to increase expression of one or more 
growth factors in epicardial cells, the contribution of these individual growth factors on AM-
mediated cardiac hyperplasia can be assessed in several ways. First, the growth factor of 
interest can be knocked down by shRNA in epicardial cells from wildtype and Admhi/hi animals. 
The supernatant from wildtype and Admhi/hi epicardial cells treated with and without shRNA can 
then be applied to either isolated neonatal cardiomyocytes, myocyte-like cells lines, or 
embryonic heart cultures and the effect on proliferation can be assessed. It is important to 
characterize the degree of knockdown achieved, since many of these growth factors have 
previously been demonstrated to be essential for proper cardiac growth and development (128, 
138, 234). Therefore, if the knockdown is too efficient, it may be difficult to assess whether the 
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increased growth factor expression is driving the hyperplasia observed in Admhi/hi animals. One 
possible way to circumvent this problem is to treat knockdown cells with increasing 
concentrations of the growth factor to determine the effect on proliferation. It may also be 
interesting to cross the Admhi/hi line to mouse lines lacking the growth factor of interest and 
assessing cardiovascular development in animals heterozygous for the particular growth factor 
in the presence of AM over-expression. The hope with this approach is that AM over-expression 
will not promote an increase in growth factor levels above those observed in wildtype animals to 
determine the contribution of this growth factor over-expression on cardiac hyperplasia in the 
Admhi/hi line. Alternatively, the growth factor receptors could be pharmacologically inhibited in 
cultures of cardiomyocytes, prior to treatment with epicardial cell supernatant from wildtype and 
Admhi/hi embryos. In the scenario in which AM over-expression is found that change the 
expression profile of growth factor receptors, an approach similar to that described above can 
be utilized. Briefly, this possibility can be investigated by applying chemical inhibitors of these 
receptors to cardiomyocyte cultures treated with supernatant from either wildtype or Admhi/hi 
epicardial cultures and the effect on proliferation can be determined. Additionally, cardiac 
development can be assessed in animals that are heterozygous for these receptors and over-
express AM in a complimentary approach to determine the effect of signaling through these 
receptors on AM-mediated cardiac hyperplasia. 
 Another mechanism by which AM may indirectly promote cardiac hyperplasia is through 
receptor transactivation. Several groups have demonstrated that GPCRs can activate receptor 
tyrosine kinases (RTK) and that it is the signaling downstream of the activated RTK that 
produces the observed outcomes (45). In order to determine whether RTK transactivation is 
occurring with AM treatment, epicardial and cardiomyocyte cell cultures could be treated with 
either vehicle or AM. Upon treatment with AM, protein could be collected from these cells and 
assayed for RTK phosphorylation. Commercial kits, such as the Mouse Phospho-Receptor 
Tyrosine Kinase Array from R&D Systems, allow users to assess the phosphorylation status of 
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many RTKs at one time, thereby minimizing the time, number of samples, and reagents needed 
to thoroughly investigate the possibility of RTK activation. If this experiment identifies one or 
more RTKs that are activated by AM, several experiments can be conducted to determine how 
this activation is occurring. To date, studies have characterized several ways in which GPCRs 
can transactivate RTKs (reviewed in (246)). One mode of RTK transactivation occurs when 
GPCR activation triggers the activation of metalloproteases within the cell, resulting in the 
release of sequestered growth factor precursors. These released growth factors can then act on 
the appropriate RTK to promote activation of the signaling cascade (187). The remaining two 
modes of RTK transactivation do not include activation of the RTK by the native ligand. Instead, 
activation of the GPCR can either promote downstream signaling that results in RTK 
phosphorylation (44), and thus activation, or a complex can form between the activated GPCR 
and the RTK, resulting in RTK activation (144). To test whether growth factor precursors are 
being released to activate the RTK, an inhibitor of the RTK can be added to the cells along with 
AM treatment, and phosphorylation of the RTK can be assessed. In order to determine whether 
signaling downstream of CLR promotes RTK phosphorylation, cells treated with AM can also be 
treated with chemical inhibitors of downstream signaling molecules and RTK phosphorylation 
can be assessed. Finally, in order to determine whether CLR is directly interacting with the RTK 
to promote activation, immunoprecipitation could be performed, utilizing a tagged version of 
CLR, since reliable antibodies are not commercially available for this receptor.  
 Finally, in addition to the interaction of AM with CLR and RAMP2 or RAMP3, it is 
possible that AM may also act through additional receptor complexes to modulate some aspects 
of cardiac development. For instance, recent work by Klein et al (110) has suggested that the 
chemokine receptor CXCR7 can function as a decoy receptor for AM. Therefore, it is possible 
that AM is interacting with CXCR7 and potentially eliciting downstream changes via alternative 
signaling pathways. Recent studies have shown that activation of other chemokine receptors, 
such as Ccr7, results in an inhibition of Wnt signaling (249). Since Wnt signaling can activate 
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the transcription of genes involved in cell proliferation, it is possible that a similar mechanism 
occurs when AM interacts with CXCR7 as a means of regulating cardiac proliferation. To test 
this possibility, in vitro studies can be performed to determine whether AM treatment in the 
presence or absence of CXCR7 alters β–catenin localization. Additionally, cells could be treated 
with Wnt pathway inhibitors, and the effect of AM over-expression or CXCR7 loss on cell 
proliferation could be assessed.  
 
Experiments related to the regulation of Adm by estrogen-induced microRNAs 
 Further exploration into the mechanisms underlying the regulation of Adm by estrogen-
induced microRNAs represents another interesting avenue of future research. The results 
presented in this dissertation indicate that regulation of Adm by estrogen-induced microRNAs 
may be largely confined to the heart. This finding raises several questions, including: how do the 
profiles of estrogen-induced microRNAs differ between the heart and other estrogen-responsive 
tissues, and which estrogen-induced microRNAs are responsible for regulating Adm expression 
in the heart. In order to address these questions, several experiments could be conducted. First, 
using RNA extracted from several tissues, the effect of estrogen on microRNA expression levels 
could be assessed by microarray. For this experiment, female mice would be subjected to 
ovariectomy before sexual maturation and divided into two groups; a control group receiving 
vehicle injections and a group injected with β–estradiol. This experimental approach allows for 
the conclusive determination of estrogen’s effect on microRNA expression across different 
tissues without the confounding variable of changing progesterone levels, which occurs in 
cycled females (76).  Once the profile of estrogen-induced microRNAs that are differentially 
expressed in the female heart is established, additional studies can be conducted to evaluate 
the relative importance of each of these remaining microRNAs in the regulation of Adm 
expression. One approach to determining the relative importance of each microRNA would be to 
 105 
treat isolated neonatal cardiomyocytes with the microRNAs of interest and determine the 
relative decrease in Adm gene expression by qRT-PCR. From this approach, one would predict 
that the largest reduction in Adm gene expression would occur with the microRNA or group of 
microRNAs that are most critical for regulating Adm expression. Finally, confirmation of these 
findings could be obtained by performing the converse experiment. In this set-up, the 
microRNAs of interest could be silenced with siRNAs, and the expression of Adm could be 
assessed, only this time, an up-regulation of Adm would be expected. 
 In addition to pursuing further mechanistic studies, additional work can be conducted to 
investigate the effect of dramatic up-regulation of Adm in the heart in the context of 
cardiovascular disease progression. Human studies have noted that the onset of menopause 
results in an increased number of cardiovascular risk factors, increasing the likelihood of a 
cardiovascular incident (43). Given the many cardioprotective properties of AM (20, 77, 78, 105, 
107, 165, 170, 171, 173, 203), it seems plausible that elevated levels of AM in females may 
offer protection in the context of cardiovascular disease. One approach that could be used to 
test whether the dramatic elevation of Adm in the female heart is cardioprotective is by 
challenging female wildtype and Admhi/hi mice with ischemia-reperfusion injury and assessing 
disease pathology. Since Adm levels differ with changing levels of estrogen during the estrus 
cycle (reported in Chapter IV), it is important to ensure that females are cycled and analyzed at 
the same point in the estrus cycle. Additionally, since Adm transcript levels are elevated by 60-
fold in the female Admhi/hi heart (see Chapter IV), it may be interesting to also compare disease 
progression between intact and ovariectomized females. Finally, if intact Admhi/hi females are 
found to be better protected against ischemia-reperfusion injury compared to ovariectomized 
Admhi/hi females, the role of estrogen in this response could be determined by infusing estrogen 
into ovariectomized mice by osmotic minipump, and again, assessing cardiovascular 
pathologies.  
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 Finally, studies could be conducted to further explore the relationship between Adm and 
other genes targeted by the same cohort of estrogen-induced microRNAs during cardiovascular 
disease. For these studies, female mice lacking either expression of several estrogen-induced 
microRNAs predicted to target the Adm 3#UTR could be generated and subjected to ischemia-
reprefusion. Then, qRT-PCR could be used to assess the expression levels of Adm and other 
genes that share a high proportion of the knocked out microRNAs in the heart. One would 
expect that Adm expression levels would be elevated in the knockout animals compared to 
wildtype controls due to the loss of estrogen-dependent negative regulation of Adm, 
recapitulating what is observed in the Admhi/hi female heart. Once the expression profiles of the 
related genes are determined, experiments can then be conducted to uncover the roles played 
by each gene in any observed differences in disease progression. Special focus should be paid 
to ion channels, as well as cell junction proteins, as highlighted in the discussion section of 
Chapter IV. 
 
Experiments pertaining to epicardial-derived AM in cardiovascular disease 
 Another potential area of study involves investigating the role of AM, in particular the 
function of epicardial-derived AM, during ischemic injury of the heart. Given the many protective 
properties of AM (19, 37, 60, 106, 108, 140, 168, 231), there has been much interest in 
determining the cardioprotective potential of AM. Several studies have demonstrated that AM 
does offer some cardioprotection as a 50% reduction of AM results in worsened cardiovascular 
disease (20, 203). These findings have led researchers to ask whether over-expression of AM 
enhances protection of the heart following injury. To date, several studies have over-expressed 
AM either by infusion or adeno-associated virus (AAV) in animals and assessed disease 
following ischemia-reperfusion injury (78, 125, 170, 237, 243). These studies have largely found 
that AM over-expression does offer a modest degree of protection. However, these studies have 
been unable to address the effect of a physiologically-relevant 3-fold elevation in AM on 
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prognosis following ischemic injury. Additionally, as our recent work has determined that the 
epicardium is a major contributor of AM in the heart (245), the contribution of epicardial-derived 
AM on cardioprotection remains unknown. This last point is of particular interest given the 
reactivation of the epicardium following injury to the adult heart (Figure 1). 
 These questions can readily be addressed using genetic mouse models available in the 
lab. In order to address the effect of a genetic 3-fold elevation of AM, Admhi/hi mice can be 
subjected to permanent ligation of the left anterior descending (LAD) artery. By opting to 
perform a permanent ligation of the artery, potential differences in reperfusion injury due to the 
antioxidant effect of AM (19, 105) can be avoided, thereby allowing for a more robust evaluation 
of the effect of AM over-expression on infarct size. This approach could also minimize the 
number of animals needed to assess the impact of AM over-expression on ischemic injury due 
to increased reproducibility of the area at risk (AAR). In the future, ischemia-reperfusion studies 
can also be performed to assess the role of elevated AM during reperfusion injury and to more 
closely mimic the human condition after coronary artery bypass surgery.  
In order to assess whether genetic over-expression of AM offers cardioprotection 
following myocardial infarction, several parameters need to be evaluated. Several studies have 
indicated that AM enhances contractility (87, 216, 217) making it prudent to assess the impact 
of AM status on heart function. Therefore, baseline echocardiograms should be obtained for 
wildtype and Admhi/hi animals prior to permanent ligation of the LAD artery. Then, 
echocardiograms can be performed 5-, 10-, and 15-days post-surgery on surviving animals to 
determine whether heart function is improved with AM over-expression. Another major factor 
that contributes to long-term prognosis following myocardial infarction is the extent of tissue 
damage in the vulnerable area. Therefore, a thorough examination of infarct size following 
ligation needs to be conducted to determine if AM over-expression reduces infarct size relative 
to wildtype animals. In order to confidently assess the impact of AM over-expression on infarct 
size, it is necessary to determine the percentage of the area at risk (AAR) that is infarcted. 
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Commonly, the AAR is determined by perfusing the heart with Evans blue dye, which will stain 
all perfused tissue, leaving the AAR unstained. After identification of the AAR, the tissue can be 
stained with triphenyl tetrazolium chloride (TTC) to identify the infarcted tissue. The reduction of 
TTC by metabolically active tissues results in the production of a red byproduct, while deceased 
tissue within the infarct is unable to catalyze this reduction resulting in a pale coloration of dead 
tissue within the infarcted region. By comparing the infarct area to the AAR for wildtype and 
Admhi/hi animals, it can be determined whether AM reduces infarct size. In addition to quantifying 
the infarct area, the effect of AM over-expression on cell death can be assessed by TUNEL and 
cleaved caspase-3 staining to corroborate the TTC staining findings. By using both of these 
staining methods, total cell death can be assessed with TUNEL staining, while the contribution 
of apoptosis to the observed cell death can be determined with cleaved caspase-3 staining.  
After determining the effect of AM over-expression on infarct size and cell death, it would 
be interesting to determine whether scar formation is altered with AM over-expression. 
Following the initial wave of cell death after an ischemic event, scar formation begins to stabilize 
the damaged area of the heart. Some studies have indicated that AM has an anti-fibrotic effect 
(168), so it is possible that AM over-expression in this model will results in reduced deposition of 
ECM and, thus, a reduction in scar formation. To establish whether AM reduces the degree of 
fibrosis following myocardial infarction, sections of the infarcted zone of the heart can be stained 
with Picrosirius Red to identify collagen fibers and the degree of fibrosis can be quantitated. 
Further support for any changes observed in fibrosis from histological assessment can be 
garnered by assessing changes in the expression of fibrosis-related genes, such as Col1a1 and 
TGF-β1, by qRT-PCR. Inflammation also plays an important role in wound healing and 
therefore, should also be considered in this model. In order to quickly assess whether 
inflammatory differences exist, histological sections stained with H&E can be examined to 
determine the extent of inflammation. If differences are observed, immunohistochemistry can be 
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utilized to identify the immune cells present in the wound to deduce whether the composition of 
inflammatory cells within the wound varies with AM expression status.    
Finally, some groups have demonstrated that the epicardium becomes reactivated 
following an injury such as myocardial infarction (52, 130, 252). During this reactivation, 
epicardial cells proliferate and undergo EMT to produce fibroblasts (252). It has also been 
suggested that the resulting EPDCs can secrete pro-angiogenic factors, thus promoting 
revascularization of the infarcted region (252). Prior studies have established that AM can 
promote angiogenesis (60, 106), and therefore, AM over-expression may improve 
revascularization of the infarct zone. This possibility can be addressed by staining heart 
sections with a marker of vascular endothelial cells, such as PECAM-1, and quantitating the 
number of vessels in the regions surrounding the infarct as well as within the infarcted zone. 
Work from our lab has revealed a proliferative role for AM in some scenarios (245). To 
determine whether AM over-expression increases proliferation of the activated epicardium, 
heart sections could be stained with phospho-Histone H3, a marker of mitosis, along with a 
marker of the epicardium, such as cytokeratin (180, 236), and the number of cells positive for 
both markers could be quantitated. Lastly, the effect of AM on EMT of the EPDCs can be 
assessed with immunohistochemistry. Specifically, heart sections of the infarcted region can be 
stained with a marker of epithelial cells, such as cytokeratin or E-cadherin (94), and a marker of 
mesenchymal cells, such as vimentin or FSP-1 (94), to identify cells transitioning from an 
epithelial phenotype to a mesenchymal fate. Together, these proposed experiments thoroughly 
characterize the effect of AM on cardiac repair following a myocardial infarction.  
In addition to characterizing the effect of globally elevated AM on cardiac repair following 
a myocardial infarction, another interesting area of future study lies in determining the 
contribution of epicardial-derived AM in this process. When the Admhi/hi line was generated, the 
stabilizing bGH 3#UTR was flanked with loxP sites (126). Thus, in the presence of Cre 
recombinase, the stabilizing 3#UTR is removed and Adm expression is re-stabilized by the 
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native 3#UTR, resulting in wildtype levels of AM (245). Therefore, the epicardial-specific Wt1-Cre 
line could be used to specifically reduce AM to wildtype levels in the epicardium, while 
maintaining AM over-expression in all other tissues. With these mice, we can then perform the 
experiments described above to determine which, if any, of these phenotypes are driven by AM 
produced by the epicardium. 
Together, the studies proposed here would further our understanding of the function of 
AM during cardiac development. Additionally, these studies would advance our knowledge of 
the signaling pathways through which AM elicits its actions during development. Finally, these 
studies would also begin to address questions regarding the effect of a 3-fold elevation of AM 
during human cardiovascular disease and explore the possibility of exploiting this pathway for 
cardiac regeneration following injury. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Epicardial reactivation following ischemic injury.  
Upon ischemic injury, the fetal gene program is reactivated in the epicardium. Expression of AM 
could potentially be increased in the epicardium by hypoxia following ischemic injury of the 
heart. Given that AM is elevated following injury to the human heart and the many protective 
properties of AM, this may represent a novel mechanism of protection, although the underlying 
mechanisms have yet to be characterized.  
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